[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 1817
1. Meister M, Schirmacher P, Dienemann H, Mechtersheimer G, Schnabel PA, Kern MA, Herpel E, Xu EC, Muley T, Thomas M, Rieker RJ: Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett; 2007 Apr 18;248(2):186-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial tumours of the thymus (thymoma, thymic carcinoma) are rare tumours of the anterior mediastinum.
  • So far, EGFR mutational status of different subtypes of epithelial tumours of the thymus has been analyzed only inappropriately.
  • Thus EGFR-expression in thymic tumours does not rely on mutations in critical functional (activation) domains of the EGFR-gene.
  • [MeSH-major] Genes, erbB-1. Thymoma / genetics. Thymus Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919868.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  •  go-up   go-down


2. Lin JP, Lu HF, Lee JH, Lin JG, Hsia TC, Wu LT, Chung JG: (-)-Menthol inhibits DNA topoisomerases I, II alpha and beta and promotes NF-kappaB expression in human gastric cancer SNU-5 cells. Anticancer Res; 2005 May-Jun;25(3B):2069-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been reported that (-)-Menthol can inhibit the growth of rat liver epithelial tumor cells and is a potent chemopreventive agent.
  • [MeSH-major] Menthol / pharmacology. NF-kappa B / biosynthesis. Stomach Neoplasms / drug therapy. Topoisomerase Inhibitors
  • [MeSH-minor] Antigens, Neoplasm / biosynthesis. Antigens, Neoplasm / genetics. Cell Death / drug effects. Cell Line, Tumor. Cell Survival / drug effects. DNA Damage. DNA Topoisomerases / biosynthesis. DNA Topoisomerases / genetics. DNA Topoisomerases, Type I / biosynthesis. DNA Topoisomerases, Type I / genetics. DNA Topoisomerases, Type II / biosynthesis. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / antagonists & inhibitors. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Gene Expression. Humans. Stereoisomerism. Topoisomerase I Inhibitors. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. MENTHOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16158947.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / NF-kappa B; 0 / Topoisomerase I Inhibitors; 0 / Topoisomerase II Inhibitors; 0 / Topoisomerase Inhibitors; 1490-04-6 / Menthol; EC 5.99.1.- / DNA Topoisomerases; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; EC 5.99.1.3 / DNA topoisomerase II beta
  •  go-up   go-down


3. Fujishiro M, Yahagi N, Kakushima N, Kodashima S, Muraki Y, Ono S, Yamamichi N, Tateishi A, Oka M, Ogura K, Kawabe T, Ichinose M, Omata M: Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases. Clin Gastroenterol Hepatol; 2007 Jun;5(6):678-83; quiz 645
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of endoscopic submucosal dissection for colorectal epithelial neoplasms in 200 consecutive cases.
  • BACKGROUND & AIMS: The clinical outcomes for endoscopic submucosal dissection (ESD), a novel endoluminal surgery for gastrointestinal neoplasm in the colorectum, are reported.
  • METHODS: ESD was performed on 186 consecutive patients with 200 colorectal epithelial neoplasms who had preoperative diagnoses of mucosal or slight submucosally invasive neoplasms.
  • The rate of en bloc resection was 91.5% (183/200), and en bloc resection with tumor-free lateral/basal margins (R0 resection) was 70.5% (141/200).
  • Two multiple-piece resections of 111 tumors (1.8%), which were successfully followed by colonoscopy (median follow-up, 18 months; range, 12-60 months), were found as locally recurrent tumors 2 and 21 months after ESD.
  • However, when considering the risks and benefits, piecemeal endoscopic resection or colorectal resection might be more appropriate for some subgroups of large flat neoplasms or those with submucosal fibrosis.
  • [MeSH-major] Colonoscopy. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Jun;5(6):674-7 [17544994.001]
  • (PMID = 17466600.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Gupta R, Balzer B, Picken M, Osunkoya AO, Shet T, Alsabeh R, Luthringer D, Paner GP, Amin MB: Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms. Am J Surg Pathol; 2009 Feb;33(2):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic implications of transcription factor Pax 2 protein and transmembrane enzyme complex carbonic anhydrase IX immunoreactivity in adult renal epithelial neoplasms.
  • Data regarding expression in renal epithelial tumors other than clear cell renal cell carcinoma (RCC) are limited, conflicting, from tissue microarrays, and do not encompass the entire spectrum or novel uncommon variants.
  • Conventional sections from 200 renal tumors comprising clear cell RCC (n=30), oncocytoma (n=17), papillary RCC (n=30), chromophobe RCC (n=50), urothelial carcinomas (n=30), collecting duct carcinomas (n=5), renal tumors with Xp11.2 translocation (n=15), tubulocystic carcinoma (n=19), and mucinous tubular spindle cell carcinoma (n=4) were immunostained for Pax 2 and CA IX.
  • Clear cell RCC (30/30, 100%), urothelial carcinoma (27/30, 90%), papillary RCC (17/30, 57%), and renal tumors with Xp11.2 translocation (6/15, 40%) exhibited membranous immunoreactivity with CA IX, whereas the other subtypes were nonreactive.
  • This suggests potential diagnostic utility of Pax 2 in distinction of (i) oncocytoma (positive) from chromophobe RCC (negative), (ii) clear cell RCC and papillary RCC (positive) from renal tumors with Xp11.2 translocation (negative), and (iii) high-grade clear cell RCC (positive) from urothelial carcinoma (negative).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / analysis. Carbonic Anhydrases / metabolism. Kidney Neoplasms / diagnosis. Neoplasms, Glandular and Epithelial / pathology. PAX2 Transcription Factor / metabolism

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941400.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / PAX2 Transcription Factor; 0 / PAX2 protein, human; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  •  go-up   go-down


5. Mukaratirwa S, Chipunza J, Chitanga S, Chimonyo M, Bhebhe E: Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe. J S Afr Vet Assoc; 2005 Jun;76(2):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe.
  • Sixty per cent (540/900) of the cases were tumours and 40% (360/900) were non-neoplastic inflammatory or degenerative diseases.
  • Thirty different histological types of tumour were diagnosed.
  • The prevalence of epithelial, mesenchymal, lymphohistiocytic and melanocytic tumours was 39.4%, 44.4%, 7.4% and 8.7%, respectively.
  • The 10 most common tumours, comprising 73.7% of all cutaneous neoplasms, were mast cell tumours, squamous cell carcinomas, perianal gland adenomas, lymphomas, benign melanomas, haemangiosarcomas, sebaceous gland adenomas, fibrosarcomas, lipomas and malignant melanomas.
  • The prevalence of various neoplasms, age of affected dogs and sites of occurrence were similar to surveys in other countries, except that in Zimbabwe there was a greater prevalence of lymphomas and of tumours associated with increased exposure to ultraviolet light (squamous cell carcinomas, haemangiosarcomas and melanomas).
  • For all classes of tumours the sex of the dog did not have any significant influence on the likelihood of developing a tumour.
  • For a dog diagnosed with a tumour located on the trunk, the tumour was significantly more likely to be an epithelial tumour than a non-epithelial tumour The occurrence of melanocytic tumours on the trunk was significantly lower than at other sites.
  • Lymphohistiocytic tumours were 10 times more likely to occur at multiple locations as opposed to single locations.
  • [MeSH-major] Dog Diseases / epidemiology. Dog Diseases / pathology. Skin Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108522.001).
  • [ISSN] 1019-9128
  • [Journal-full-title] Journal of the South African Veterinary Association
  • [ISO-abbreviation] J S Afr Vet Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] South Africa
  •  go-up   go-down


6. Ziuganov VV, Popkovich EG: [Arctic teleost fishes with canceled accelerated senescence program are a potential source of stress protectors and cancer drugs]. Izv Akad Nauk Ser Biol; 2005 Sep-Oct;(5):578-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trials of the biologic prepared from this secretion in salmons with epithelioma, guinea pigs with affected skin, and mice with transplantable tumors demonstrated a good therapeutic effect of the biologic.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16240755.001).
  • [ISSN] 1026-3470
  • [Journal-full-title] Izvestiia Akademii nauk. Seriia biologicheskaia
  • [ISO-abbreviation] Izv. Akad. Nauk. Ser. Biol.
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protective Agents; 0 / Proteins
  •  go-up   go-down


7. Noskova V, Ahmadi S, Asander E, Casslén B: Ovarian cancer cells stimulate uPA gene expression in fibroblastic stromal cells via multiple paracrine and autocrine mechanisms. Gynecol Oncol; 2009 Oct;115(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Expression of uPA mRNA is massively up-regulated in the stroma of poorly differentiated ovarian tumors.
  • We hypothesized that this expression was induced by paracrine signals from the epithelial tumor cells, and established an in vitro model of ovarian cancer microenvironment to study intercellular cross-talk.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Communication / physiology. Fibroblasts / cytology. Ovarian Neoplasms / pathology. RNA, Messenger / biosynthesis. Stromal Cells / cytology. Urokinase-Type Plasminogen Activator / genetics
  • [MeSH-minor] Cell Line, Tumor. Coculture Techniques. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19631971.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  •  go-up   go-down


8. de Souza A, Gibson LE, Wada DA, Yi ES, Medeiros F, Camilleri MJ, el-Azhary R, Micallef IN: Resolution of CD8+ lymphomatoid papulosis after surgical excision of the type AB-thymoma. Am J Dermatopathol; 2009 Jul;31(5):475-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The type AB thymoma is an epithelial neoplasm composed of both type A (lymphocyte-poor) and type B (lymphocyte-rich) areas.
  • [MeSH-major] Lymphomatoid Papulosis / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology. Thymoma / pathology. Thymus Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Antigens, CD / metabolism. Biomarkers, Tumor / analysis. Blotting, Southern. CD8-Positive T-Lymphocytes / immunology. Chemokines / metabolism. Humans. Immunohistochemistry. Male. Polymerase Chain Reaction. Receptors, Chemokine / metabolism

  • Genetic Alliance. consumer health - Lymphomatoid papulosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542925.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / Chemokines; 0 / Receptors, Chemokine
  •  go-up   go-down


9. Kim DJ, Yang WI, Kim SH, Park IK, Chung KY: Expression of neurotrophin receptors in surgically resected thymic epithelial tumors. Eur J Cardiothorac Surg; 2005 Oct;28(4):611-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of neurotrophin receptors in surgically resected thymic epithelial tumors.
  • OBJECTIVE: Neurotrophins are known to exert a variety of pleiotropic responses in different target tissues, but little is known about their effect on thymic epithelial tumors.
  • Therefore, we analyzed the expression of neurotrophin receptors in surgically resected thymic epithelial tumors and evaluated their clinical relevance.
  • METHODS: The expression of neurotrophin receptors (Trk-A, Trk-B, Trk-C and p75(NTR)) in thymic epithelial tumors was evaluated in 99 consecutive patients based on immunohistochemical staining.
  • RESULTS: Thymic tumors were classified as type A (n=6), AB (n=21), B1 (n=15), B2 (n=24), B3 (n=22) or C (n=11).
  • All tumors, except one type C thymoma, demonstrated cytoplasmic Trk-A immunostaining, and no thymic tumors showed Trk-B or Trk-C immunoreactivity. p75(NTR) immunostaining demonstrated characteristic patterns according to the WHO subtypes of thymomas.
  • All type A and type AB thymomas showed p75(NTR) immunoreactivity, except one type A tumor.
  • Tumor-related survival at 5 and 10 years was 95.5 and 89.5%, respectively, in p75(NTR)-positive thymomas and 82.8 and 77.2%, respectively, in p75(NTR)-negative thymomas; however, the differences were not statistically significant (P=0.14).
  • Further study of p75(NTR) expression may aid in understanding the biology of thymic epithelial tumors.
  • [MeSH-major] Receptors, Nerve Growth Factor / analysis. Thymoma / chemistry. Thymus Neoplasms / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry / methods. Male. Middle Aged. Neoplasm Proteins / analysis. Nerve Tissue Proteins / analysis. Prognosis. Receptor, trkA / analysis. Receptor, trkB / analysis. Receptor, trkC / analysis. Receptors, Growth Factor / analysis. Survival Analysis. Thymus Gland / metabolism. Thymus Gland / pathology

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125946.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / NGFR protein, human; 0 / Neoplasm Proteins; 0 / Nerve Tissue Proteins; 0 / Receptors, Growth Factor; 0 / Receptors, Nerve Growth Factor; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB; EC 2.7.10.1 / Receptor, trkC
  •  go-up   go-down


10. Choi YD, Lee JS, Choi C, Park CS, Nam JH: Ovarian neuroendocrine carcinoma, non-small cell type, associated with serous carcinoma. Gynecol Oncol; 2007 Mar;104(3):747-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroendocrine carcinoma of the non-small cell type of the ovary is a rare aggressive tumor, interestingly associated with either a surface epithelial tumor or teratoma.
  • Pathology examination showed a 6.5 cm in greatest dimension ovarian tumor composed of neuroendocrine carcinoma of the non-small cell type and serous carcinoma.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian small cell carcinoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229461.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Grapsa D, Kairi-Vassilatou E, Hasiakos D, Kondi-Pafiti A: Ovarian mucinous cystadenoma with extended calcification in an 11-year-old girl: case report and review of the literature. Clin Exp Obstet Gynecol; 2006;33(3):181-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of ovarian masses in childhood and adolescence are non-epithelial in origin, with a predominance of germ cell tumors, while epithelial neoplasms comprise a small proportion of the total (approximately 15-20%).
  • Careful evaluation of the remaining pathological features of the tumor is needed in order to avoid misinterpreting this relatively non-specific finding as a feature of malignancy.
  • [MeSH-major] Cystadenoma, Mucinous / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089585.001).
  • [ISSN] 0390-6663
  • [Journal-full-title] Clinical and experimental obstetrics & gynecology
  • [ISO-abbreviation] Clin Exp Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 11
  •  go-up   go-down


12. Gurevich LE, Kazantseva IA, Korsakova NA, Tsar'kov PV, Polishchuk LO: [Expression of type 1 and type 2 mucins in colonic epithelial tumors]. Arkh Patol; 2007 Mar-Apr;69(2):12-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of type 1 and type 2 mucins in colonic epithelial tumors].
  • [MeSH-major] Adenocarcinoma. Antigens, Neoplasm / biosynthesis. Colonic Neoplasms. Intestinal Mucosa. Mucins / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Male. Middle Aged. Mucin-1. Mucin-2. Prognosis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17642184.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC1 protein, human; 0 / MUC2 protein, human; 0 / Mucin-1; 0 / Mucin-2; 0 / Mucins
  •  go-up   go-down


13. Arab M, Khayamzadeh M, Hashemi M, Hosseini M, Tabatabaeefar M, Anbiaee R, Anvari N, Ebrahimi M, Akbari ME: Crude and age-specific incidence rate patterns for histopathologic subtypes of ovarian cancer in Iran. Arch Iran Med; 2010 May;13(3):203-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial tumors displayed the highest age specific incidence rate, followed by germ cell tumors.
  • Serous epithelial tumors were the most common in the epithelial group.
  • [MeSH-major] Ovarian Neoplasms / epidemiology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Age Distribution. Age of Onset. Aged. Biopsy, Needle. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Iran / epidemiology. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Neoplasms, Germ Cell and Embryonal / epidemiology. Neoplasms, Germ Cell and Embryonal / pathology. Prognosis. Registries. Survival Analysis

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20433224.001).
  • [ISSN] 1735-3947
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


14. Civit T, Klein O, Baylac F: [Lacrimal gland epithelial tumors]. Neurochirurgie; 2010 Apr-Jun;56(2-3):152-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lacrimal gland epithelial tumors].
  • [Transliterated title] Tumeurs épithéliales de la glande lacrymale.
  • Epithelial tumors of the lacrimal gland account for 50% of the expansive lesions of the lacrimal fossa.
  • [MeSH-major] Eye Neoplasms / surgery. Lacrimal Apparatus / surgery. Neoplasms, Glandular and Epithelial / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20303130.001).
  • [ISSN] 1773-0619
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, Casimiro MC, Wang C, Fortina P, Addya S, Pestell RG, Martinez-Outschoorn UE, Sotgia F, Lisanti MP: The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle; 2009 Dec;8(23):3984-4001
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma.
  • Here, we propose a new model for understanding the Warburg effect in tumor metabolism.
  • Our hypothesis is that epithelial cancer cells induce the Warburg effect (aerobic glycolysis) in neighboring stromal fibroblasts.
  • Epithelial cancer cells could then take up these energy-rich metabolites and use them in the mitochondrial TCA cycle, thereby promoting efficient energy production (ATP generation via oxidative phosphorylation), resulting in a higher proliferative capacity.
  • In this alternative model of tumorigenesis, the epithelial cancer cells instruct the normal stroma to transform into a wound-healing stroma, providing the necessary energy-rich micro-environment for facilitating tumor growth and angiogenesis.
  • In essence, the fibroblastic tumor stroma would directly feed the epithelial cancer cells, in a type of host-parasite relationship.
  • In this scenario, the epithelial tumor cells "corrupt" the normal stroma, turning it into a factory for the production of energy-rich metabolites.
  • This alternative model is still consistent with Warburg's original observation that tumors show a metabolic shift towards aerobic glycolysis.
  • Importantly, a loss of stromal Cav-1 in human breast cancers is associated with tumor recurrence, metastasis, and poor clinical outcome.
  • Thus, an absence of stromal Cav-1 may be a biomarker for the "Reverse Warburg Effect," explaining its powerful predictive value.
  • [MeSH-major] Breast Neoplasms / metabolism. Fibroblasts / metabolism. Glycolysis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19923890.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30-CA-56036; United States / NIAMS NIH HHS / AR / R01-AR-055660; United States / NCI NIH HHS / CA / R01-CA-098779; United States / NCI NIH HHS / CA / R01-CA-107382; United States / NCI NIH HHS / CA / R01-CA-120876; United States / NCI NIH HHS / CA / R01-CA-70896; United States / NCI NIH HHS / CA / R01-CA-75503; United States / NCI NIH HHS / CA / R01-CA-80250; United States / NCI NIH HHS / CA / R01-CA-86072
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Annexins; 0 / Caveolin 1; 0 / Tenascin; EC 1.1.1.27 / L-Lactate Dehydrogenase; EC 2.7.1.40 / Pyruvate Kinase
  •  go-up   go-down


16. Fishman A, Shalom-Paz E, Fejgin M, Gaber E, Altaras M, Amiel A: Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):261-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing the genetic changes detected in the primary and secondary tumor sites of ovarian cancer using comparative genomic hybridization.
  • Our objective was to compare the genetic abnormalities in the primary tumors of epithelial ovarian cancer and their associated secondary peritoneal implants using comparative genomic hybridization (CGH).
  • Dissected tissue samples from the primary tumor and from the metastatic peritoneal implant were obtained at initial surgical staging and analyzed in each case.
  • We used CGH as this technique allows the entire genome of the tumor to be examined simultaneously for chromosomal imbalances without the need for tissue culture or targeting of specific loci.
  • Comparing the genomes of the primary tumors with the metastatic samples showed four cases with a balanced metastatic CGH profile while the primary site was aberrant.
  • The cytogenetic patterns in six of the seven primary tumors showed complex karyotypic changes, unlike the inconsistent findings that were associated with the secondary sites.
  • Such genomic heterogeneity between the primary and secondary sites may indicate that the secondary peritoneal implants are de novo carcinogenesis occurrences.
  • [MeSH-major] Chromosome Aberrations. DNA Damage. DNA, Neoplasm / genetics. Neoplasm Metastasis / genetics. Nucleic Acid Hybridization. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Karyotyping. Peritoneal Neoplasms / genetics. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823109.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


17. Akbulut M, Zekioglu O, Terek MC, Ozdemir N: Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor. Arch Gynecol Obstet; 2008 Sep;278(3):283-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoadenofibroma of the endometrium: a rare variant of benign mullerian mixed tumor.
  • OBJECTIVE: Adenofibroma is a form of mixed mesodermal tumor in which epithelial and stromal components are benign, and usually arises in the endometrium of postmenopausal women.
  • CONCLUSION: We suggest that uterine adenofibromas with lipomatous areas belong to the family of mixed tumor of Mullerian origin.
  • [MeSH-major] Adenofibroma / pathology. Endometrial Neoplasms / pathology. Mixed Tumor, Mullerian / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18236054.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Kellar KA, Lorenzi MV, Ho CP, You D, Wen ML, Ryseck RP, Oppenheimer S, Fink BE, Vite GD, Rowley BR, Yu C, Bol DK, Lee FY, Wong TW: Constitutively active receptor tyrosine kinases as oncogenes in preclinical models for cancer therapeutics. Mol Cancer Ther; 2006 Jun;5(6):1571-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Receptor tyrosine kinases (RTK) remain an area of therapeutic interest because of their role in epithelial tumors, and experimental models specific to these targets are highly desirable.
  • A CD8HER2 fusion protein was shown to form disulfide-mediated homodimers and to transform fibroblasts and epithelial cells.
  • CD8RTK fusion proteins transform rat kidney epithelial cells and impart phenotypes that may reflect signaling specificity inherent in the native receptors.
  • Transgenic expression of CD8HER2 and CD8Met in mice resulted in the formation of salivary and mammary gland tumors.
  • The transgenic tumors allow the derivation of allograft tumors and cell lines that are sensitive to inhibition by small molecule kinase inhibitors.
  • This approach provides excellent cell and tumor models for the characterization of signaling properties of diverse RTKs and for the evaluation of rationally designed antagonists targeting these kinases.
  • [MeSH-major] Antigens, CD8 / metabolism. Gene Expression Regulation, Neoplastic / physiology. Mammary Neoplasms, Animal / genetics. Receptor, ErbB-2 / metabolism. Recombinant Fusion Proteins / genetics. Salivary Gland Neoplasms / genetics
  • [MeSH-minor] Animals. Blotting, Western. Cell Transformation, Neoplastic / genetics. Dimerization. Disease Models, Animal. Disulfides / pharmacology. Epithelial Cells / cytology. Epithelial Cells / metabolism. Female. Fibroblasts / cytology. Fibroblasts / metabolism. Humans. Mice. Mice, Inbred BALB C. Mice, Nude. Mice, Transgenic. Peptide Fragments / immunology. Plasmids. Proto-Oncogene Proteins c-met / genetics. Proto-Oncogene Proteins c-met / metabolism. Rats. Receptor Protein-Tyrosine Kinases / metabolism. Transfection

  • MedlinePlus Health Information. consumer health - Salivary Gland Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16818516.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD8; 0 / CD8 antigen, alpha chain; 0 / Disulfides; 0 / Peptide Fragments; 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / Proto-Oncogene Proteins c-met; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


19. Parajuli N, Doppler W: Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs. In Vitro Cell Dev Biol Anim; 2009 Sep;45(8):442-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precision-cut slice cultures of tumors from MMTV-neu mice for the study of the ex vivo response to cytokines and cytotoxic drugs.
  • Ex vivo analysis of signaling pathways operating in tumor tissue is complicated by the three-dimensional structure, in particular by stroma-epithelial interactions.
  • Studies performed with pure populations of tumor cells usually do not take into account this issue.
  • One possibility to preserve the tissue architecture is the use of tumor slices.
  • By using precision cut slices of defined thickness, we were able to establish culture conditions for tumor material obtained from MMTV-neu transgenic mice, which allow the study of the action of cytokines and cytotoxic drugs for up to 24 h.
  • The slices were also a convenient source for the establishment of explant cultures of tumor epithelial cells.
  • It is concluded that cultivation of precision-cut tumor slices provides a convenient way for the ex vivo molecular analysis of MMTV-neu tumor tissue under conditions which closely simulate the situation in vivo and can provide an alternative to in vivo experiments.
  • [MeSH-major] Cytokines / pharmacology. Cytostatic Agents / pharmacology. Mammary Neoplasms, Animal / metabolism. Mammary Neoplasms, Animal / pathology. Tissue Culture Techniques
  • [MeSH-minor] Animals. Doxorubicin / pharmacology. Epithelial Cells / drug effects. Epithelial Cells / pathology. Interferon Regulatory Factor-1 / drug effects. Interferon Regulatory Factor-1 / metabolism. Mammary Tumor Virus, Mouse. Mice. Mice, Transgenic. Receptor, ErbB-2 / metabolism. STAT1 Transcription Factor / drug effects. STAT1 Transcription Factor / metabolism. Signal Transduction / drug effects. Signal Transduction / physiology. Suppressor of Cytokine Signaling 1 Protein. Suppressor of Cytokine Signaling Proteins / drug effects. Suppressor of Cytokine Signaling Proteins / metabolism. Tumor Cells, Cultured

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Biol Toxicol. 2002;18(3):205-19 [12083426.001]
  • [Cites] Life Sci. 1995;57(21):1887-901 [7475939.001]
  • [Cites] J Biol Chem. 2008 Aug 8;283(32):22089-96 [18524780.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8697-703 [15623655.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(11):1987-94 [17719831.001]
  • [Cites] Liver Int. 2006 Jun;26(5):604-12 [16762006.001]
  • [Cites] J Virol. 2008 Jan;82(2):999-1010 [17977977.001]
  • [Cites] Eur J Biochem. 1999 Jan;259(1-2):25-31 [9914471.001]
  • [Cites] J Pharmacol Toxicol Methods. 1997 Oct;38(2):59-69 [9403776.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):614-21 [17602728.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):204-16 [16498443.001]
  • [Cites] Respir Res. 2007 Jun 14;8:43 [17567922.001]
  • [Cites] Toxicology. 2000 Nov 16;153(1-3):221-53 [11090959.001]
  • [Cites] BMC Cancer. 2007 Jul 25;7:136 [17651480.001]
  • [Cites] J Cell Sci. 1989 Jul;93 ( Pt 3):491-500 [2606940.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Sep;3(9):651-62 [12209125.001]
  • [Cites] Gynecol Oncol. 2008 Mar;108(3):591-7 [18177927.001]
  • [Cites] BMC Cancer. 2008 Apr 24;8:119 [18435859.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):389-97 [17446858.001]
  • [Cites] J Biol Chem. 2004 Dec 17;279(51):53272-81 [15489221.001]
  • [Cites] Traffic. 2007 Dec;8(12):1815-28 [17892529.001]
  • [Cites] Cell Biol Toxicol. 1998 Jun;14(3):175-90 [9689491.001]
  • [Cites] Breast Cancer Res. 2003;5(3):130-5 [12793893.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2004 Jan-Feb;40(1-2):14-21 [15180438.001]
  • [Cites] Cell Tissue Res. 2008 Jun;332(3):489-98 [18386065.001]
  • [Cites] Cell Biol Int. 1999;23(3):157-61 [10562436.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2002 Jun;38(6):326-33 [12513120.001]
  • [Cites] BMC Cancer. 2006 Apr 07;6:86 [16603054.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10578-82 [1359541.001]
  • (PMID = 19533258.001).
  • [ISSN] 1543-706X
  • [Journal-full-title] In vitro cellular & developmental biology. Animal
  • [ISO-abbreviation] In Vitro Cell. Dev. Biol. Anim.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / W 1101
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cytokines; 0 / Cytostatic Agents; 0 / Interferon Regulatory Factor-1; 0 / STAT1 Transcription Factor; 0 / Socs1 protein, mouse; 0 / Stat1 protein, mouse; 0 / Suppressor of Cytokine Signaling 1 Protein; 0 / Suppressor of Cytokine Signaling Proteins; 80168379AG / Doxorubicin; EC 2.7.10.1 / Erbb2 protein, mouse; EC 2.7.10.1 / Receptor, ErbB-2
  •  go-up   go-down


20. Leve F, de Souza W, Morgado-Díaz JA: A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell-cell adhesion and actin cytoskeleton organization in epithelial cancer cells. J Pharmacol Exp Ther; 2008 Dec;327(3):777-88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A cross-link between protein kinase A and Rho-family GTPases signaling mediates cell-cell adhesion and actin cytoskeleton organization in epithelial cancer cells.
  • Disassembly of the apical junctional complex (AJC) together with actin cytoskeleton alterations are among the initial events for the development of epithelial cancer.
  • Thus, our findings demonstrate a central role of a regulatory cascade that integrates PKA and Rho-family GTPases in the AJC disassembly and actin organization in tumor epithelial cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Adhesion. Cyclic AMP-Dependent Protein Kinases / metabolism. Cytoskeleton / metabolism. Epithelial Cells / ultrastructure. Signal Transduction. rho GTP-Binding Proteins / metabolism
  • [MeSH-minor] Actins / metabolism. Caco-2 Cells. Colonic Neoplasms / pathology. Humans. Intercellular Junctions / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791066.001).
  • [ISSN] 1521-0103
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; EC 2.7.11.11 / Cyclic AMP-Dependent Protein Kinases; EC 3.6.5.2 / rho GTP-Binding Proteins
  •  go-up   go-down


21. Akihara Y, Shimoyama Y, Kawasako K, Komine M, Hirayama K, Kagawa Y, Omachi T, Matsuda K, Okamoto M, Kadosawa T, Taniyama H: Immunohistochemical evaluation of canine ovarian tumors. J Vet Med Sci; 2007 Jul;69(7):703-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of canine ovarian tumors.
  • Canine ovarian tumors (epithelial tumor, sex-cord stromal tumor, germ cell tumor) classifying into 9 histological types were examined immunohistochemically using placental alkaline phosphatase (PLAP), cytokeratin7 (CK7), desmin, S100, AE1/AE3, inhibin alpha, vimentin, and alfa feto-protein (AFP).
  • The papillary and tubular types observed in epithelial tumors were immunoreactive for desmin and AE1/AE3.
  • The solid type, nest type, cord type, palisade type, cystic type and spindle type, which were observed in sex-cord stromal tumors, showed a positive immunoreaction for S100 but little or no positive immunoreaction for inhibin alpha with an exception of positive result in the palisade type.
  • Most of the sex-cord stromal tumors were AE1/AE3-positive except for the palisade type.
  • In the cobblestone type observed in germ cell tumors, only vimentin and AFP were positive.
  • The present study elucidated the detailed histological and immunohistochemical characteristics of canine ovarian tumors.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675800.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


22. Parikh AH, Khan SH, Wright JD Jr, Oh KT: Systemic non-Hodgkin's lymphoma simulating primary intraocular lymphoma. Am J Ophthalmol; 2005 Mar;139(3):573-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Diagnostic enucleation and histopathologic studies revealed findings consistent with primary intraocular lymphoma including intraretinal, subretinal, and subretinal pigment epithelial tumor cells without involvement of the choroid.
  • [MeSH-major] Eye Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Retinal Neoplasms / diagnosis. Vitreous Body / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15767087.001).
  • [ISSN] 0002-9394
  • [Journal-full-title] American journal of ophthalmology
  • [ISO-abbreviation] Am. J. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Downs LS Jr, Lima PH, Bliss RL, Blomquist CH: Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer. J Soc Gynecol Investig; 2005 Oct;12(7):539-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cathepsins B and D activity and activity ratios in normal ovaries, benign ovarian neoplasms, and epithelial ovarian cancer.
  • OBJECTIVE: Cathepsins B (CB) and D (CD) belong to a family of proteases felt to be important in tumor metastasis and invasion.
  • It has been suggested that both enzymes play a role the progression of epithelial ovarian cancer and they have been investigated as potential biomarkers for ovarian cancer.
  • Tissue specimens were divided into four groups: normal ovary, benign neoplasm, early-stage (I/II) cancer, and late-stage (III/IV) cancer.
  • CONCLUSIONS: CB activity is associated with invasive ovarian neoplasm.
  • [MeSH-major] Cathepsin B / metabolism. Cathepsin D / metabolism. Ovarian Neoplasms / enzymology. Ovary / enzymology
  • [MeSH-minor] Female. Humans. Isoenzymes. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16202931.001).
  • [ISSN] 1556-7117
  • [Journal-full-title] Journal of the Society for Gynecologic Investigation
  • [ISO-abbreviation] J. Soc. Gynecol. Investig.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Isoenzymes; EC 3.4.22.1 / Cathepsin B; EC 3.4.23.5 / Cathepsin D
  •  go-up   go-down


24. Samaila MO: Malignant tumours of childhood in Zaria. Afr J Paediatr Surg; 2009 Jan-Jun;6(1):19-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant tumours of childhood in Zaria.
  • BACKGROUND: The increased prevalence of hitherto uncommon tumours in children in our geographic setting formed the basis for this study.
  • MATERIALS AND METHODS: An eight year (2000-2007) consecutive analysis of malignant tumours in children ages 0 to 15 years in a referral University laboratory.
  • Tumours were characterised histologically into tissues of origin and categorised into three age groups; <1 year, 1-5 years and 6-15 years.
  • RESULT: 189 children with malignant tumours were analysed.
  • Tumours of mesenchymal origin were the commonest (115: 60.8%) while epithelial tumours including germ cell tumours accounted for 74 (39.2%) cases.
  • The age group 1-5 years had the highest epithelial tumours while age group 6-15 years had the most tumours with 102 (54%) cases overall.
  • The five commonest tumours over-all were rhabdomyosarcoma, Burkitt lymphoma, retinoblastoma, non-Hodgkin's lymphoma and nephroblastoma.
  • Germ cell tumours affected the ovary predominantly and two of the endodermal sinus tumour cases were seen in the testis of an eighteen month child and sacrococcygeum of a 5 year old girl, respectively.
  • The vascular tumours included epithelioid haemangioendothelioma, haemangioblastoma and Dabska tumour and they accounted for (5.8%) of all tumours seen.
  • The commonest sites of occurrence of these tumours were the oculo-orbital, jaw, head and neck regions with 82 cases (43.4%) while lymph nodes were involved in 31 (16.4%) cases.
  • CONCLUSION: The distribution and occurrence of malignant tumours in children is age related.
  • Lymphomas were the commonest tumours overall while retinoblastoma and Burkitt lymphoma were the commonest tumours affecting children below 5 years and 6-10 years old, respectively, in our centre.
  • The head region and lymph nodes were the sites of predilection for majority of these tumours.
  • [MeSH-major] Lymphoma / epidemiology. Neoplasms / epidemiology. Neoplasms / pathology. Retinal Neoplasms / epidemiology. Retinoblastoma / epidemiology

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661660.001).
  • [ISSN] 0974-5998
  • [Journal-full-title] African journal of paediatric surgery : AJPS
  • [ISO-abbreviation] Afr J Paediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nigeria
  •  go-up   go-down


25. Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA: Muc4/MUC4 functions and regulation in cancer. Future Oncol; 2009 Dec;5(10):1631-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The membrane mucin MUC4 (human) is abundantly expressed in many epithelia, where it is proposed to play a protective role, and is overexpressed in some epithelial tumors.
  • The roles of MUC4 in tumors suggest that it may be valuable as a tumor marker or target for therapy.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FASEB J. 2008 Apr;22(4):966-81 [18024835.001]
  • [Cites] FASEB J. 2008 Aug;22(8):3035-45 [18492726.001]
  • [Cites] Biochim Biophys Acta. 2008 Oct;1783(10):1728-36 [18573283.001]
  • [Cites] Br J Cancer. 2009 Jan 27;100(2):344-51 [19127263.001]
  • [Cites] Exp Cell Res. 2009 Feb 15;315(4):638-48 [19038249.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2845-52 [19293191.001]
  • [Cites] Crit Rev Oncog. 2008;14(2-3):177-96 [19409062.001]
  • [Cites] J Cell Biochem. 2009 Jul 1;107(4):797-802 [19388004.001]
  • [Cites] J Biol Chem. 2003 May 30;278(22):20338-44 [12668667.001]
  • [Cites] J Biol Chem. 2003 Aug 8;278(32):30142-7 [12748185.001]
  • [Cites] J Biol Chem. 2003 Sep 19;278(38):36942-52 [12855694.001]
  • [Cites] Biochem J. 2004 Feb 1;377(Pt 3):701-8 [14583090.001]
  • [Cites] Cancer Res. 2004 Jan 15;64(2):622-30 [14744777.001]
  • [Cites] Hepatology. 2004 Jan;39(1):220-9 [14752841.001]
  • [Cites] Mod Pathol. 2004 Feb;17(2):150-7 [14657954.001]
  • [Cites] Laryngoscope. 2004 Aug;114(8 Pt 2 Suppl 101):1-32 [15284539.001]
  • [Cites] Oncogene. 2004 Jul 29;23(34):5729-38 [15184872.001]
  • [Cites] Inflammation. 2004 Apr;28(2):67-76 [15379212.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2148-57 [11596032.001]
  • [Cites] Curr Biol. 2001 Nov 13;11(22):1739-48 [11719215.001]
  • [Cites] Am J Respir Cell Mol Biol. 2002 Apr;26(4):447-52 [11919081.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):791-6 [12090430.001]
  • [Cites] Prog Nucleic Acid Res Mol Biol. 2002;71:149-85 [12102554.001]
  • [Cites] Int J Cancer. 2002 Jun 20;99(6):783-91 [12115478.001]
  • [Cites] Eur J Biochem. 2002 Aug;269(15):3637-44 [12153560.001]
  • [Cites] Cell Microbiol. 2002 Aug;4(8):515-29 [12174086.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32258-67 [12077147.001]
  • [Cites] Oncogene. 2002 Oct 24;21(49):7524-32 [12386815.001]
  • [Cites] Biochem J. 2002 Nov 15;368(Pt 1):41-8 [12186632.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284(4):L671-9 [12495942.001]
  • [Cites] Mol Cell. 2003 Feb;11(2):495-505 [12620236.001]
  • [Cites] Nature. 2003 Mar 20;422(6929):322-6 [12646923.001]
  • [Cites] Biochem Pharmacol. 2003 May 1;65(9):1419-25 [12732353.001]
  • [Cites] Cancer Res. 1999 May 1;59(9):2229-36 [10232613.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1633-8 [15494719.001]
  • [Cites] J Biol Chem. 1980 Jan 25;255(2):783-90 [7356644.001]
  • [Cites] J Biol Chem. 1980 Dec 25;255(24):12051-9 [7440586.001]
  • [Cites] J Biol Chem. 1984 Apr 25;259(8):4866-77 [6715325.001]
  • [Cites] Biochem J. 1990 Jan 1;265(1):121-9 [2302161.001]
  • [Cites] J Biol Chem. 1990 May 25;265(15):8505-10 [2111320.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Mar 15;175(2):414-22 [1673336.001]
  • [Cites] J Biol Chem. 1992 Aug 15;267(23):16341-6 [1379596.001]
  • [Cites] J Biol Chem. 1994 Apr 22;269(16):11950-5 [8163496.001]
  • [Cites] Cell. 1994 Jul 15;78(1):5-8 [8033211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8132-6 [8058768.001]
  • [Cites] J Biol Chem. 1997 Dec 26;272(52):33245-54 [9407114.001]
  • [Cites] Biochem J. 1998 Mar 1;330 ( Pt 2):737-44 [9480884.001]
  • [Cites] Biochem J. 1998 Oct 15;335 ( Pt 2):457-63 [9761747.001]
  • [Cites] Clin Cancer Res. 1998 Nov;4(11):2669-76 [9829729.001]
  • [Cites] J Biol Chem. 1998 Dec 25;273(52):35228-37 [9857062.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5263-6 [10026131.001]
  • [Cites] Biochem J. 1999 Mar 1;338 ( Pt 2):325-33 [10024507.001]
  • [Cites] Nat Med. 2000 Apr;6(4):443-6 [10742152.001]
  • [Cites] J Biol Chem. 2000 Jun 9;275(23):17800-7 [10837499.001]
  • [Cites] Int J Cancer. 2000 Aug 15;87(4):480-6 [10918186.001]
  • [Cites] Oncogene. 2000 Sep 7;19(38):4354-61 [10980611.001]
  • [Cites] J Cell Physiol. 2000 Nov;185(2):310-6 [11025453.001]
  • [Cites] J Biol Chem. 2000 Oct 27;275(43):33929-36 [10938282.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):641-9 [10880365.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21885-94 [11283019.001]
  • [Cites] J Biol Chem. 2001 Aug 17;276(33):30923-33 [11418607.001]
  • [Cites] Biochem J. 2005 Feb 15;386(Pt 1):35-45 [15461591.001]
  • [Cites] Cancer Res. 2005 Jan 15;65(2):473-82 [15695389.001]
  • [Cites] J Clin Pathol. 2005 Aug;58(8):845-52 [16049287.001]
  • [Cites] Oncogene. 2005 Sep 8;24(40):6143-54 [16007204.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Respir Res. 2006;7:39 [16551361.001]
  • [Cites] Biosci Rep. 2006 Feb;26(1):55-67 [16779668.001]
  • [Cites] Mol Biol Cell. 2006 Jul;17(7):2931-41 [16624867.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19310-9 [16690615.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4257-64 [16857800.001]
  • [Cites] Mod Pathol. 2006 Oct;19(10):1386-94 [16880776.001]
  • [Cites] J Biol Chem. 2006 Sep 29;281(39):29411-20 [16891313.001]
  • [Cites] Oncogene. 2007 Jan 4;26(1):30-41 [16799633.001]
  • [Cites] Lung Cancer. 2007 Feb;55(2):195-203 [17126950.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):433-6 [17234748.001]
  • [Cites] Biochem J. 2007 Feb 15;402(1):81-91 [17037983.001]
  • [Cites] Arch Pathol Lab Med. 2007 Apr;131(4):593-8 [17425390.001]
  • [Cites] J Biol Chem. 2007 Aug 3;282(31):22638-50 [17553805.001]
  • [Cites] Annu Rev Physiol. 2008;70:431-57 [17850209.001]
  • (PMID = 20001800.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA052498-17; United States / NCI NIH HHS / CA / CA52498; United States / NCI NIH HHS / CA / R01 CA052498-17; United States / NCI NIH HHS / CA / R01 CA052498; United States / NCI NIH HHS / CA / CA052498-16; United States / NCI NIH HHS / CA / R01 CA052498-16
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MUC4 protein, human; 0 / Mucin-4
  • [Number-of-references] 86
  • [Other-IDs] NLM/ NIHMS171897; NLM/ PMC2825673
  •  go-up   go-down


26. Maestá I, Michelin OC, Traiman P, Hokama P, Rudge MV: Primary non-gestational choriocarcinoma of the uterine cervix: a case report. Gynecol Oncol; 2005 Jul;98(1):146-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pelvic examination realized under anesthetic revealed a tumor mass occupying the uterine cervix.
  • CONCLUSION: Primary non-gestational uterine cervical choriocarcinoma may arise from germ cell tumor or epithelial tissue.
  • [MeSH-major] Choriocarcinoma, Non-gestational / pathology. Uterine Cervical Neoplasms / pathology


27. Korst RJ, Kansler AL, Christos PJ, Mandal S: Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg; 2009 May;87(5):1641-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis.
  • Adjuvant radiotherapy after complete resection of localized, invasive thymic epithelial tumors is considered by many to be the standard of care, despite little supporting literature.
  • Analysis of data from 592 patients with completely resected stage II or III thymic epithelial tumors, however, revealed no statistically significant reduction in recurrence after adjuvant radiotherapy (odds ratio 1.05; 95% confidence interval: 0.63 to 1.75; p = 0.840).
  • [MeSH-major] Thymus Neoplasms / radiotherapy
  • [MeSH-minor] Carcinoma / pathology. Carcinoma / radiotherapy. Carcinoma / surgery. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Invasiveness. Neoplasm Staging. Radiotherapy, Adjuvant / methods. Secondary Prevention

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • COS Scholar Universe. author profiles.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379938.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 42
  •  go-up   go-down


28. Pachmann K, Dengler R, Lobodasch K, Fröhlich F, Kroll T, Rengsberger M, Schubert R, Pachmann U: An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer. J Cancer Res Clin Oncol; 2008 Jan;134(1):59-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An increase in cell number at completion of therapy may develop as an indicator of early relapse: quantification of circulating epithelial tumor cells (CETC) for monitoring of adjuvant therapy in breast cancer.
  • Circulating epithelial tumor cells (CETC) were quantified before and after each second cycle of the therapy regimen, between the anthracycline and the taxane block of the regimen and in some cases repeatedly during CMF treatment.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Epithelial Cells / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplastic Cells, Circulating / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2007 Apr;16(2):211-8 [17291754.001]
  • [Cites] Clin Chem Lab Med. 2001 Sep;39(9):811-7 [11601678.001]
  • [Cites] BMJ. 2005 Jan 29;330(7485):205-6 [15677633.001]
  • [Cites] Clin Cancer Res. 2001 Dec;7(12):4102-8 [11751508.001]
  • [Cites] Lancet. 1999 Jul 17;354(9174):197-202 [10421301.001]
  • [Cites] Breast Cancer Res Treat. 2003 Dec;82(3):199-206 [14703067.001]
  • [Cites] Cancer Res. 1999 Aug 1;59(15):3776-82 [10446995.001]
  • [Cites] Cancer. 2005 Mar 1;103(5):884-91 [15666325.001]
  • [Cites] Nat Med. 2005 Aug;11(8):824-5 [16079872.001]
  • [Cites] Ann Oncol. 2003 Jun;14(6):849-55 [12796021.001]
  • [Cites] Crit Rev Oncol Hematol. 2005 Sep;55(3):167-75 [16039867.001]
  • [Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]
  • [Cites] Exp Hematol. 2004 Oct;32(10):891-904 [15504544.001]
  • [Cites] BMJ. 2005 Jan 29;330(7485):217 [15649903.001]
  • [Cites] N Engl J Med. 2004 Aug 19;351(8):781-91 [15317891.001]
  • [Cites] World J Surg Oncol. 2005 Mar 31;3(1):18 [15801980.001]
  • [Cites] Eur J Surg Oncol. 2002 Sep;28(6):615-9 [12359196.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5657; author reply 5657-8 [16061886.001]
  • [Cites] Clin Cancer Res. 2004 Feb 15;10(4):1392-400 [14977842.001]
  • [Cites] Anticancer Res. 2004 Nov-Dec;24(6):4211-6 [15736474.001]
  • [Cites] Clin Cancer Res. 2005 May 15;11(10):3678-85 [15897564.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R975-9 [16280045.001]
  • [Cites] Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003372 [15846660.001]
  • [Cites] MMW Fortschr Med. 2002 Oct 10;144(41):37-9 [12474359.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8152-62 [15623589.001]
  • (PMID = 17611779.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bridged-Ring Compounds; 0 / Taxoids; 094ZI81Y45 / Tamoxifen; 1605-68-1 / taxane; 3Z8479ZZ5X / Epirubicin; 8N3DW7272P / Cyclophosphamide; U3P01618RT / Fluorouracil; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


29. Xu D, Liu D, Zhang Z, Zhang Y, Li Y, Liu X, Jia Q, Zheng L, Song G: Gamma Knife surgery in the management of orbital tumors. J Neurosurg; 2010 Dec;113 Suppl:34-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery in the management of orbital tumors.
  • OBJECT: The authors evaluated the results they obtained using Gamma Knife surgery (GKS) in patients with orbital tumors.
  • METHODS: This is a retrospective clinical evaluation of 202 patients with orbital tumors who were treated with GKS between September 1995 and October 2008.
  • There were 84 meningiomas, 38 epithelial tumors of the lacrimal gland, 23 schwannomas, 18 malignant choroidal melanomas, 12 optic nerve gliomas, 11 orbital metastases, 10 pseudotumors of the orbit, 3 retinoblastomas, and 3 cases of fibromatosis.
  • The tumor margin dose ranged from 10 to 40 Gy.
  • RESULTS: At a median follow-up period of 34.5 ± 14.7 months (range 12-114 months), tumor shrinkage was observed in 118 patients (58.4%) and stable tumor size in 71 patients (35.1%).
  • Regularly scheduled neuroimaging studies demonstrated evidence of tumor progression in only 13 patients (6.4%): 9 of these patients underwent repeated GKS and 4 received surgical treatment.
  • CONCLUSIONS: Gamma Knife surgery provides an effective management strategy in patients with orbital tumors; it achieves excellent preservation of neurological function and is associated with few treatment-related complications.
  • [MeSH-major] Meningioma / surgery. Neurilemmoma / surgery. Optic Nerve Glioma / surgery. Orbital Neoplasms / surgery. Radiosurgery / instrumentation
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Meningeal Neoplasms / surgery. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121785.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Richardsen E, Uglehus RD, Due J, Busch C, Busund LT: COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol; 2010 Jun;34(3):316-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ki67 was included as a measure of growth fraction of tumor cells.
  • METHODS: Digital video analysis images from tumor cell areas and tumor stromal areas were analyzed on formalin fixed, paraffin-embedded and immunohistochemical stained cancer specimens from 59 patients: 32 patients with metastases and 27 patients without clinical, biochemical, or radiological evidence of metastases within 10 years after diagnosis.
  • RESULTS: In primary cancers in the metastatic group, COX-2, TGF-beta and Ki67 were stronger expressed in epithelial tumor cell and tumor stromal areas compared with non-metastatic cancers (for all markers, p<0.0001).
  • High intensity of COX-2 staining in tumor areas was strongly associated with death from prostate cancer in univariate analyses (hazard ratio [HR] 95% CI, 4.0 (1.1-14.5)).
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Interleukin-10 / metabolism. Ki-67 Antigen / metabolism. Prostatic Neoplasms / metabolism. Transforming Growth Factor beta / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma / metabolism. Carcinoma / mortality. Carcinoma / pathology. Humans. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Metastasis. Rectal Neoplasms / metabolism. Rectal Neoplasms / secondary. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / secondary

  • Genetic Alliance. consumer health - Prostate cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20409773.001).
  • [ISSN] 1877-783X
  • [Journal-full-title] Cancer epidemiology
  • [ISO-abbreviation] Cancer Epidemiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Transforming Growth Factor beta; 130068-27-8 / Interleukin-10; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


31. Rivet J, Mourah S, Murata H, Mounier N, Pisonero H, Mongiat-Artus P, Teillac P, Calvo F, Janin A, Dosquet C: VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer; 2008 Jan 15;112(2):433-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma.
  • BACKGROUND: Tumor angiogenesis is a dynamic process that plays a major role in cancer progression.
  • METHODS: Total VEGF protein levels were quantified by enzyme-linked immunosorbent assay (ELISA) in tumor tissue samples from surgical specimens of 65 patients with clear cell RCC.
  • At the cellular level the VEGF isoforms VEGFR-1 and VEGFR-2 mRNA were quantified by real-time quantitative reverse-transcriptase polymerase chain reaction (RT-PCR) in laser-microdissected tumoral epithelial as stromal cells and in corresponding normal tissue compartments.
  • In laser-microdissected epithelial cells, VEGF(121) and VEGFR-1 mRNA expressions were higher in RCC than in corresponding nontumoral kidney (P= .007 and P= .002, respectively); they were also higher in stromal cells of RCC compared with nontumoral kidney (P= .02 and P= .003, respectively).
  • There was no differential VEGFR-2 expression in epithelial or in stromal cells of tumoral or nontumoral kidney.
  • By immunofluorescent labeling VEGF and VEGFR-1 colocalized on RCC tumor epithelial and stromal cells.
  • CONCLUSIONS: Combined laser microdissection and quantitative RT-PCR, as triple immunofluorescent labeling, underlined the preferential expression of the most soluble VEGF isoform, VEGF(121), and its receptor VEGFR-1, but not VEGFR-2, in epithelial and stromal cells of RCC.
  • [MeSH-major] Carcinoma, Renal Cell / chemistry. Kidney Neoplasms / chemistry. Vascular Endothelial Growth Factor A / analysis. Vascular Endothelial Growth Factor Receptor-1 / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Epithelial Cells / chemistry. Female. Fluorescent Antibody Technique. Humans. Keratins / analysis. Keratins / genetics. Male. Microdissection. Middle Aged. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Stromal Cells / chemistry. Vascular Endothelial Growth Factor Receptor-2 / analysis. Vascular Endothelial Growth Factor Receptor-2 / genetics

  • Genetic Alliance. consumer health - Renal cell carcinoma.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041056.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Vascular Endothelial Growth Factor A; 68238-35-7 / Keratins; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2
  •  go-up   go-down


32. Röcken C, Röhl FW, Diebler E, Lendeckel U, Pross M, Carl-McGrath S, Ebert MP: The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol Biomarkers Prev; 2007 Jun;16(6):1206-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Local expression of AT1R, AT2R, and angiotensin-converting enzyme (ACE) was investigated by immunohistochemistry in tumor and corresponding nontumor specimens obtained from 100 patients with gastric cancer, and compared with the ACE insertion/deletion gene polymorphism.
  • AT1R and AT2R were found in the tumor epithelial cells of 26 (26%) and 95 (95%) patients, respectively.
  • In intestinal type gastric cancer, its expression correlated with the N category (P = 0.009) and the International Union Against Cancer tumor stage (P = 0.024).
  • AT1R+ intestinal type gastric cancers had a larger number of lymph node metastases (P = 0.026), a higher International Union Against Cancer tumor stage (P = 0.032), and a shorter survival time (P = 0.009) than AT1R- tumors.
  • When the ACE genotype was included, the relative risk of having lymph node metastases increased considerably in AT1R+ tumors being heterozygous or homozygous for the ACE D allele (odds ratio, 19.00; 95% confidence interval, 1.45-248.24).
  • [MeSH-major] Adenocarcinoma / pathology. Angiotensin II / metabolism. Genetic Predisposition to Disease. Peptidyl-Dipeptidase A / genetics. Receptors, Angiotensin / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17548686.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Angiotensin; 11128-99-7 / Angiotensin II; EC 3.4.15.1 / Peptidyl-Dipeptidase A
  •  go-up   go-down


33. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, Han L, Gershenson DM, Sood AK: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res; 2006 Mar 15;12(6):1707-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We sought to determine the role of epithelial (tumor cell-derived) and stromal (host-derived) expression of MMPs in predicting the clinical outcome of patients with epithelial ovarian cancer (EOC).
  • EXPERIMENTAL DESIGN: MMP-2, MMP-9, and membrane type 1 (MT1)-MMP expression was evaluated using immunohistochemistry in 90 invasive EOCs, and samples were scored for epithelial and stromal staining.
  • RESULTS: High expression of MMP-2, MMP-9, and MT1-MMP in tumor epithelium was detected in 54%, 97%, and 100% of cases, and in stromal compartments, in 38%, 70%, and 38% of cases, respectively.
  • Kaplan-Meier analysis showed that high epithelial and stromal expression of MMP-2, MMP-9, and MT1-MMP were each significantly associated with shorter disease-specific survival (DSS; P < 0.01).
  • On tree-structured survival analysis, patients with strong epithelial MT1-MMP expression had the shortest DSS, whereas patients with moderate epithelial MT1-MMP and low stromal MMP-9 expression had the longest DSS (P < 0.01).
  • On multivariate analysis, high stromal expression of MMP-9 (P = 0.01) and MT1-MMP (P = 0.04), strong epithelial MT1-MMP (P = 0.01) and high stage (P = 0.04) were independent predictors of poor DSS.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res Treat. 2000 Sep;63(2):105-15 [11097087.001]
  • [Cites] Clin Exp Metastasis. 1999;17(10):799-808 [11089877.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2040-9 [11597382.001]
  • [Cites] Trends Cell Biol. 2001 Nov;11(11):S37-43 [11684441.001]
  • [Cites] Gynecol Oncol. 2002 Jan;84(1):126-34 [11748988.001]
  • [Cites] Mol Cell Endocrinol. 2002 Feb 22;187(1-2):39-45 [11988310.001]
  • [Cites] Nat Rev Cancer. 2002 Mar;2(3):161-74 [11990853.001]
  • [Cites] J Natl Cancer Inst. 2002 Aug 7;94(15):1134-42 [12165638.001]
  • [Cites] Surgery. 2002 Aug;132(2):220-5 [12219015.001]
  • [Cites] Clin Cancer Res. 2002 Sep;8(9):2924-32 [12231537.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(5):417-20 [14584660.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):559-67 [14766248.001]
  • [Cites] Mol Cancer Res. 2004 Feb;2(2):73-80 [14985463.001]
  • [Cites] J Biol Chem. 2004 Apr 2;279(14):13564-74 [14729679.001]
  • [Cites] Am J Obstet Gynecol. 2004 Apr;190(4):899-909 [15118611.001]
  • [Cites] Clin Cancer Res. 2004 Oct 1;10(19):6512-21 [15475438.001]
  • [Cites] Lab Invest. 1983 Dec;49(6):636-49 [6317982.001]
  • [Cites] FASEB J. 1990 Apr 1;4(6):1577-90 [2180767.001]
  • [Cites] Cell. 1991 Jan 25;64(2):327-36 [1703045.001]
  • [Cites] Biometrics. 1992 Jun;48(2):411-25 [1637970.001]
  • [Cites] Breast Cancer Res Treat. 1993;24(3):185-93 [8435474.001]
  • [Cites] Lab Invest. 1993 Sep;69(3):312-21 [8377473.001]
  • [Cites] Int J Cancer. 1994 Feb 15;56(4):500-5 [8112886.001]
  • [Cites] J Cell Sci. 1994 Feb;107 ( Pt 2):477-86 [8207074.001]
  • [Cites] Int J Cancer. 1994 Jul 1;58(1):50-6 [8014015.001]
  • [Cites] J Histochem Cytochem. 1994 Jul;42(7):945-51 [8014478.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5331-8 [7890645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Mar 28;92(7):2730-4 [7708715.001]
  • [Cites] Int J Cancer. 1996 Jan 3;65(1):57-62 [8543396.001]
  • [Cites] Int J Cancer. 1996 Feb 20;69(1):9-16 [8600068.001]
  • [Cites] J Biochem. 1996 Feb;119(2):209-15 [8882706.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2968-75 [8918494.001]
  • [Cites] Invasion Metastasis. 1996;16(3):150-9 [9186550.001]
  • [Cites] Cancer. 1997 Oct 15;80(8):1457-63 [9338470.001]
  • [Cites] Cell. 1997 Nov 14;91(4):439-42 [9390552.001]
  • [Cites] Hum Pathol. 1998 Feb;29(2):155-65 [9490275.001]
  • [Cites] Int J Oncol. 1998 Mar;12(3):569-76 [9472094.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):315-21 [10408832.001]
  • [Cites] J Biol Chem. 1999 Jul 30;274(31):21491-4 [10419448.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):91-8 [10502432.001]
  • [Cites] Gynecol Oncol. 2004 Dec;95(3):437-48 [15581944.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3193-9 [15833850.001]
  • [Cites] Cancer Res. 2005 Aug 1;65(15):6910-8 [16061675.001]
  • [Cites] J Pathol. 1999 Nov;189(3):300-8 [10547590.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):369-76 [10831344.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):673-81 [10995877.001]
  • [Cites] Cell. 2000 Oct 27;103(3):481-90 [11081634.001]
  • [Cites] Am J Clin Pathol. 2001 Apr;115(4):517-24 [11293899.001]
  • (PMID = 16551853.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA109298; United States / NCI NIH HHS / CA / 1P50CA83639; United States / NCI NIH HHS / CA / R01 CA110793; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA11079301; United States / NCI NIH HHS / CA / CA10929801
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.- / Matrix Metalloproteinases; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.35 / Matrix Metalloproteinase 9; EC 3.4.24.80 / Matrix Metalloproteinase 14
  • [Other-IDs] NLM/ NIHMS310734; NLM/ PMC3202606
  •  go-up   go-down


34. Navarro BG, Parada AC, Alvarez P, Leon A, Santana E, Bada A, Figueredo R, Iznaga-Escobar N, Perez R: Local and systemic toxicity of h-R3, an anti-epidermal growth factor receptor monoclonal antibody, labeled with 188osmiun after the intracerebral administration in rats. Exp Toxicol Pathol; 2005 Mar;56(4-5):313-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This receptor is over-expressed in the majority of tumors of epithelial origin, including glioblastomas.
  • 188Rhenium (188Re) constitutes an ideal radionuclide for imagining and radioimmunotherapy, and its toxicity is known, nevertheless, it is unknown if 188Os, as 188Re's daughter, has any local or systemic toxicity effect when it is administered intracerebrally for treating intracranial tumors.

  • Hazardous Substances Data Bank. OSMIUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816360.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Radioisotopes; 2E7M255OPY / Osmium; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


35. Agoston AT, Liang CW, Richkind KE, Fletcher JA, Vargas SO: Trisomy 18 is a consistent cytogenetic feature in pilomatricoma. Mod Pathol; 2010 Aug;23(8):1147-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilomatricoma, also known as 'calcifying epithelioma of Malherbe', is a common skin adnexal tumor that mimics hair growth.
  • This aberration was corroborated by interphase fluorescence in situ hybridization, using a chromosome 18 pericentromeric probe, in the basaloid epithelial component of 7 of 11 pilomatricomas, including the index case.
  • Trisomy 18 was present in a small subset of cells, suggesting a role in pilomatricoma progression, rather than in tumor initiation.
  • We conclude that trisomy 18 is a consistent feature in pilomatricoma, suggesting that genes carried on this chromosome, such as that for the antiapoptotic oncoprotein BCL2, may have a role in the growth and differentiation of this benign self-limited tumor.
  • [MeSH-major] Chromosomes, Human, Pair 18. Hair Diseases / genetics. Pilomatrixoma / genetics. Skin Neoplasms / genetics. Trisomy

  • Genetic Alliance. consumer health - Trisomy 18.
  • MedlinePlus Health Information. consumer health - Hair Problems.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495544.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


36. Lim KT, Cosgrave N, Hill AD, Young LS: Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1. Breast Cancer Res; 2006;8(3):R33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Increased Raf phosphorylation was also observed in primary human breast cultures derived from ER-positive and ER-negative breast tumours.
  • AT1 receptor was found to be expressed in the cell membrane of breast tumour epithelial cells.
  • [MeSH-major] Breast Neoplasms / physiopathology. Receptor, Angiotensin, Type 1 / physiology. Receptors, Estrogen / physiology
  • [MeSH-minor] Cell Proliferation. Cell Survival. Cyclic AMP / metabolism. Female. Humans. Mitogen-Activated Protein Kinase Kinases / metabolism. Phosphorylation. RNA, Small Interfering. Signal Transduction. Tumor Cells, Cultured

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Endocrinol. 2000 Oct;14(10):1649-60 [11043579.001]
  • [Cites] Circ Res. 2000 Nov 24;87(11):E44-52 [11090554.001]
  • [Cites] Endocrinology. 2000 Dec;141(12):4503-11 [11108261.001]
  • [Cites] Mol Endocrinol. 2002 Jan;16(1):70-84 [11773440.001]
  • [Cites] Mol Endocrinol. 2002 Jan;16(1):100-15 [11773442.001]
  • [Cites] J Steroid Biochem Mol Biol. 2002 Feb;80(2):231-8 [11897506.001]
  • [Cites] J Biol Chem. 2003 Jan 24;278(4):2701-12 [12421825.001]
  • [Cites] J Cell Physiol. 2003 Aug;196(2):370-7 [12811831.001]
  • [Cites] J Biol Chem. 2004 Jun 25;279(26):27008-16 [15090535.001]
  • [Cites] Br J Cancer. 2004 Nov 1;91(9):1687-93 [15477868.001]
  • [Cites] J Clin Endocrinol Metab. 1990 Aug;71(2):398-404 [2166070.001]
  • [Cites] Endocrinology. 1992 Sep;131(3):1305-12 [1505465.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 30;91(18):8517-21 [8078914.001]
  • [Cites] Nature. 1995 May 18;375(6528):247-50 [7746328.001]
  • [Cites] Hypertension. 1996 Mar;27(3 Pt 2):476-80 [8613189.001]
  • [Cites] EMBO J. 1996 Mar 15;15(6):1292-300 [8635462.001]
  • [Cites] Eur J Endocrinol. 1996 Sep;135(3):367-73 [8890730.001]
  • [Cites] J Biol Chem. 1997 May 2;272(18):11902-7 [9115251.001]
  • [Cites] Br J Cancer. 1997;75(9):1279-83 [9155046.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Jun 9;235(1):99-102 [9196043.001]
  • [Cites] Endocrinology. 1997 Sep;138(9):4030-3 [9275096.001]
  • [Cites] Mol Endocrinol. 1999 Feb;13(2):307-19 [9973260.001]
  • [Cites] Endocrinology. 1999 Mar;140(3):1385-91 [10067866.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4686-91 [10200323.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Sep 16;263(1):257-62 [10486286.001]
  • [Cites] Mol Endocrinol. 2004 Dec;18(12):2854-65 [15231873.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):277-89 [15486047.001]
  • [Cites] Steroids. 2005 May-Jun;70(5-7):361-3 [15862818.001]
  • [Cites] Mol Endocrinol. 2005 Aug;19(8):1951-9 [15705661.001]
  • [Cites] J Cell Physiol. 2000 Jul;184(1):27-36 [10825231.001]
  • [Cites] Mol Pharmacol. 2000 Sep;58(3):608-13 [10953055.001]
  • [Cites] Circ Res. 2000 Oct 13;87(8):677-82 [11029403.001]
  • (PMID = 16805920.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / Receptor, Angiotensin, Type 1; 0 / Receptors, Estrogen; E0399OZS9N / Cyclic AMP; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases
  • [Other-IDs] NLM/ PMC1557727
  •  go-up   go-down


37. Horinouchi H, Asakura K, Kimura Y, Takeuchi K, Kawamura M, Watanabe M, Eguchi K, Kobayashi K: [Prognosis of surgically treated thymic epithelial tumors]. Nihon Geka Gakkai Zasshi; 2006 Nov;107(6):262-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognosis of surgically treated thymic epithelial tumors].
  • This study was performed to clarify the prognosis of patients with surgically treated thymic epithelial tumors.
  • Pathologic review was done according to the WHO classification of tumors of the thymus.
  • Patients characteristics were: 76 male and 55 fimale; average age 53 (range 20-80) years; tumor stage was stage I in 42, stage II in 43, stage III in 23, stage IVa in 15, stage IVb in 1, and thymic carcinoma (squamous cell carcinoma) in 7 based on Masaoka's staging.
  • The prognosis of patients with thymic epithelial tumors after resection is thought to be determined by histologic classification and clinical invasiveness.
  • [MeSH-major] Carcinoma / surgery. Thymus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Time Factors. World Health Organization

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17147284.001).
  • [ISSN] 0301-4894
  • [Journal-full-title] Nihon Geka Gakkai zasshi
  • [ISO-abbreviation] Nihon Geka Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


38. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D: Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem; 2010 Nov;58(11):1015-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis.
  • Serum amyloid A (SAA) is an acute phase protein which is expressed primarily in the liver as a part of the systemic response to various injuries and inflammatory stimuli; its expression in ovarian tumors has not been described.
  • Here, we investigated the expression of SAA in human benign and malignant ovarian epithelial tumors.
  • Expression was increased gradually as epithelial cells progressed through benign and borderline adenomas to primary and metastatic adenocarcinomas.
  • [MeSH-major] Carcinoma / genetics. Carcinoma / pathology. Gene Expression Regulation, Neoplastic. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology. Serum Amyloid A Protein / genetics. Serum Amyloid A Protein / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. C-Reactive Protein / metabolism. CA-125 Antigen / blood. Cell Line, Tumor. Female. Humans. Middle Aged. Neoplasm Metastasis. Ovary / cytology. Ovary / metabolism. Ovary / pathology. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1983 Nov;43(11):5379-89 [6604576.001]
  • [Cites] Ann Intern Med. 1979 Sep;91(3):383-90 [289303.001]
  • [Cites] Scand J Immunol. 1984 Mar;19(3):193-8 [6200925.001]
  • [Cites] Biochem Biophys Res Commun. 1991 May 15;176(3):1100-5 [2039494.001]
  • [Cites] DNA Cell Biol. 1991 Nov;10(9):651-61 [1755958.001]
  • [Cites] J Biol Chem. 1992 Feb 25;267(6):3862-7 [1740433.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3186-90 [8159722.001]
  • [Cites] Genomics. 1994 Jan 15;19(2):228-35 [8188253.001]
  • [Cites] J Exp Med. 1994 Jul 1;180(1):203-9 [7516407.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):650-60 [8080047.001]
  • [Cites] J Immunol. 1995 Aug 1;155(3):1184-90 [7636186.001]
  • [Cites] Lab Invest. 1998 May;78(5):535-9 [9605178.001]
  • [Cites] J Histochem Cytochem. 1998 Dec;46(12):1377-84 [9815279.001]
  • [Cites] J Rheumatol. 1999 Apr;26(4):785-90 [10229397.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Eur J Immunol. 2005 Mar;35(3):718-26 [15724247.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 13;330(3):989-98 [15809093.001]
  • [Cites] Proteomics. 2005 Sep;5(14):3790-7 [16121334.001]
  • [Cites] Int J Oncol. 2005 Nov;27(5):1361-9 [16211233.001]
  • [Cites] J Histochem Cytochem. 2006 Jan;54(1):63-73 [16116035.001]
  • [Cites] Arthritis Rheum. 2006 Jan;54(1):105-14 [16385502.001]
  • [Cites] Mol Cell Endocrinol. 2006 Mar 9;247(1-2):4-21 [16297528.001]
  • [Cites] J Immunol. 2006 Oct 15;177(8):5585-94 [17015746.001]
  • [Cites] Biomed Environ Sci. 2007 Feb;20(1):33-40 [17458139.001]
  • [Cites] J Clin Oncol. 2008 Feb 20;26(6):995-1005 [18195328.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Apr 4;368(2):368-73 [18237545.001]
  • [Cites] FEBS Lett. 2008 Mar 5;582(5):579-85 [18243142.001]
  • [Cites] Int J Gynecol Cancer. 2008 Sep-Oct;18(5):985-95 [18028381.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2199-208 [19307507.001]
  • [Cites] Br J Cancer. 2009 Jul 21;101(2):335-41 [19536090.001]
  • [Cites] Cancer. 2010 Feb 15;116(4):843-51 [20041483.001]
  • [Cites] J Cancer Res Clin Oncol. 2010 Jul;136(7):1079-88 [20082099.001]
  • [Cites] Eur Urol. 2010 May;57(5):859-66 [19747761.001]
  • [Cites] J Clin Pathol. 1986 Jul;39(7):794-7 [3734116.001]
  • [Cites] Curr Opin Hematol. 2000 Jan;7(1):64-9 [10608507.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Feb 16;268(2):405-8 [10679217.001]
  • [Cites] Int J Cancer. 2001 May 15;92(4):497-502 [11304683.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1224-9 [11830469.001]
  • [Cites] Am J Pathol. 2002 Apr;160(4):1223-8 [11943707.001]
  • [Cites] J Histochem Cytochem. 1984 Mar;32(3):322-8 [6363521.001]
  • (PMID = 20713982.001).
  • [ISSN] 1551-5044
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / Serum Amyloid A Protein; 9007-41-4 / C-Reactive Protein
  • [Other-IDs] NLM/ PMC2958134
  •  go-up   go-down


39. Mistrangelo M, Bellò M, Mobiglia A, Beltramo G, Cassoni P, Milanesi E, Cornaglia S, Pelosi E, Giunta F, Sandrucci S, Mussa A: Feasibility of the sentinel node biopsy in anal cancer. Q J Nucl Med Mol Imaging; 2009 Feb;53(1):3-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: Anal cancer is a rare neoplasm.
  • RESULTS: Histology revealed 23 squamous carcinomas, 10 basaloid carcinomas, 1 squamous carcinoma with basaloid areas and 1 spinocellular epithelioma associated with areas of Bowen's disease.
  • [MeSH-major] Anus Neoplasms / diagnosis. Sentinel Lymph Node Biopsy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Feasibility Studies. Female. Follow-Up Studies. Humans. Inguinal Canal / pathology. Lymphatic Metastasis / diagnosis. Male. Middle Aged. Neoplasm Staging. Recurrence

  • Genetic Alliance. consumer health - Anal Cancer.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337684.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


40. Xu J, Zhang S, You C, Wang X, Zhou Q: Microvascular density and vascular endothelial growth factor have little correlation with prognosis of craniopharyngioma. Surg Neurol; 2006;66 Suppl 1:S30-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is histologically a benign epithelial tumor located in the supersellar cistern that often presents aggressive growth and repeated recurrence.
  • METHODS: The cohorts consisted of 32 patients with AE and 31 patients with SP tumor.
  • CONCLUSIONS: Microvascular density and VEGF in craniopharyngioma tissue have no correlation with prognosis of the tumor, which may be explained by the minimal blood circulation in the craniopharyngioma.
  • Adamantine epithelioma showed more tendency to recur than SP.
  • [MeSH-major] Craniopharyngioma / blood supply. Craniopharyngioma / metabolism. Neoplasm Recurrence, Local / etiology. Pituitary Neoplasms / blood supply. Pituitary Neoplasms / metabolism. Vascular Endothelial Growth Factor A / metabolism

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16904996.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


41. Yang J, Moses MA: Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle; 2009 Aug;8(15):2347-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lcn2 has been shown to induce the epithelial to mesenchymal transition (EMT) in breast cancer cells and to promote breast tumor invasion.
  • The potential roles of Lcn2 in epithelial tumors as well as leukemia are also reviewed and discussed here.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell. 2005 Dec 29;123(7):1293-305 [16377569.001]
  • [Cites] Biochem J. 2005 Oct 15;391(Pt 2):441-8 [16060857.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Feb;7(2):131-42 [16493418.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2490-7 [16381001.001]
  • [Cites] Mol Cell Proteomics. 2006 Aug;5(8):1471-83 [16733264.001]
  • [Cites] Int J Cancer. 2007 Jun 1;120(11):2426-34 [17294443.001]
  • [Cites] J Clin Pathol. 2007 May;60(5):555-61 [17412867.001]
  • [Cites] Breast Cancer Res Treat. 2008 Apr;108(3):389-97 [17554627.001]
  • [Cites] J Clin Invest. 2008 Apr;118(4):1468-78 [18317594.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1481-9 [18311905.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1540-7 [18392050.001]
  • [Cites] Leuk Lymphoma. 2008 May;49(5):984-8 [18464118.001]
  • [Cites] Cancer Res. 2008 Aug 1;68(15):6100-8 [18676832.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 16;105(37):14058-63 [18768801.001]
  • [Cites] Oncogene. 2008 Oct 16;27(47):6110-9 [18663364.001]
  • [Cites] Clin Cancer Res. 2008 Oct 15;14(20):6440-8 [18927283.001]
  • [Cites] Int J Cancer. 2008 Dec 15;123(12):2856-64 [18798264.001]
  • [Cites] J Exp Clin Cancer Res. 2008;27:83 [19077278.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3913-8 [19237579.001]
  • [Cites] J Immunol. 2009 Apr 15;182(8):4947-56 [19342674.001]
  • [Cites] EMBO J. 2009 Apr 8;28(7):866-76 [19229297.001]
  • [Cites] J Histochem Cytochem. 2009 May;57(5):513-21 [19188485.001]
  • [Cites] PLoS Genet. 2009 Apr;5(4):e1000460 [19390610.001]
  • [Cites] Lab Invest. 2009 May;89(5):531-48 [19308044.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):9-24 [11058743.001]
  • [Cites] Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 [11058770.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 31;98(16):9265-70 [11459932.001]
  • [Cites] Science. 2001 Aug 3;293(5531):829-34 [11486081.001]
  • [Cites] Cancer Res. 2001 Aug 15;61(16):5979-84 [11507038.001]
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37258-65 [11486009.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7792-7 [11691794.001]
  • [Cites] JAMA. 2002 Apr 17;287(15):1972-81 [11960540.001]
  • [Cites] Cancer Res. 2002 May 15;62(10):2890-6 [12019169.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4352-63 [12154040.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1033-43 [12453412.001]
  • [Cites] Mol Cell. 2002 Nov;10(5):1045-56 [12453413.001]
  • [Cites] Cell. 2003 Apr 18;113(2):207-19 [12705869.001]
  • [Cites] Int J Oncol. 2003 Sep;23(3):681-91 [12888904.001]
  • [Cites] Cancer Res. 2003 Dec 15;63(24):8614-22 [14695172.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):14-25 [15305371.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):100-12 [15305381.001]
  • [Cites] J Proteome Res. 2004 Sep-Oct;3(5):1042-55 [15473694.001]
  • [Cites] FEBS Lett. 1992 Dec 21;314(3):386-8 [1281792.001]
  • [Cites] J Biol Chem. 1993 May 15;268(14):10425-32 [7683678.001]
  • [Cites] Gut. 1996 Mar;38(3):414-20 [8675096.001]
  • [Cites] Biochem J. 1996 Aug 15;318 ( Pt 1):1-14 [8761444.001]
  • [Cites] J Dent Res. 1996 Aug;75(8):1553-63 [8906123.001]
  • [Cites] Genomics. 1997 Oct 1;45(1):17-23 [9339356.001]
  • [Cites] Cancer Lett. 1998 Jan 9;122(1-2):209-14 [9464512.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):565-72 [9842963.001]
  • [Cites] Histochem J. 1999 Jul;31(7):433-41 [10475571.001]
  • [Cites] Nature. 2004 Dec 16;432(7019):917-21 [15531878.001]
  • [Cites] FEBS Lett. 2005 Jan 31;579(3):773-7 [15670845.001]
  • [Cites] J Clin Invest. 2005 Mar;115(3):610-21 [15711640.001]
  • [Cites] J Biol Chem. 2005 Apr 8;280(14):13641-7 [15691834.001]
  • [Cites] Oncogene. 2005 May 5;24(20):3246-56 [15735695.001]
  • [Cites] Clin Cancer Res. 2005 Aug 1;11(15):5390-5 [16061852.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 7;103(6):1834-9 [16446425.001]
  • (PMID = 19571677.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA118764-05; United States / NCI NIH HHS / CA / R01 CA118764; United States / NCI NIH HHS / CA / R01 CA118764-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acute-Phase Proteins; 0 / Estrogen Receptor alpha; 0 / LCN2 protein, human; 0 / Ligands; 0 / Lipocalins; 0 / Proto-Oncogene Proteins; E1UOL152H7 / Iron; EC 3.4.24.35 / Matrix Metalloproteinase 9
  • [Other-IDs] NLM/ NIHMS278018; NLM/ PMC3381736
  •  go-up   go-down


42. Hutcheson IR, Knowlden JM, Hiscox SE, Barrow D, Gee JM, Robertson JF, Ellis IO, Nicholson RI: Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells. Breast Cancer Res; 2007;9(4):R50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In clinical tissue all samples demonstrated cytoplasmic tumour epithelial HRGbeta1 protein staining, with expression correlating with EGFR positivity and activation of both AKT and ERK1/2.
  • This may have implications for the effectiveness of anti-EGFR therapies in breast cancer as HRGbeta1 is enriched in many EGFR-positive breast tumours.
  • [MeSH-major] Antineoplastic Agents, Hormonal / pharmacology. Breast Neoplasms / drug therapy. Drug Resistance, Neoplasm. Neuregulin-1 / pharmacology. Protein Kinase Inhibitors / pharmacology. Quinazolines / pharmacology. Tamoxifen / pharmacology
  • [MeSH-minor] Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Blotting, Western. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cell Proliferation. Dimerization. Female. Humans. Immunoprecipitation. Mitogen-Activated Protein Kinases / metabolism. Neoplasm Invasiveness. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Receptor, ErbB-2 / metabolism. Receptor, ErbB-3 / metabolism. Signal Transduction. Trastuzumab


43. Newman S, Edwards PA: High-throughput analysis of chromosome translocations and other genome rearrangements in epithelial cancers. Genome Med; 2010;2(3):19
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-throughput analysis of chromosome translocations and other genome rearrangements in epithelial cancers.
  • Genes that are broken or fused by structural changes to the genome are an important class of mutation in the leukemias and sarcomas but have been largely overlooked in the common epithelial cancers.
  • This reveals more clearly than before the extent to which many cancer genomes are rearranged and how much these rearrangements contribute to the mutational burden of epithelial tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Nat Rev Cancer. 2007 Apr;7(4):233-45 [17361217.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Science. 2007 Sep 14;317(5844):1500 [17872428.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Nature. 2009 Dec 24;462(7276):1005-10 [20033038.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):722-9 [18438408.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Genome Res. 2009 Feb;19(2):167-77 [19056696.001]
  • [Cites] Nature. 2009 Apr 9;458(7239):719-24 [19360079.001]
  • [Cites] J Pathol. 2010 Jan;220(2):244-54 [19921709.001]
  • [Cites] Oncogene. 2008 May 22;27(23):3345-59 [18084325.001]
  • (PMID = 20236477.001).
  • [ISSN] 1756-994X
  • [Journal-full-title] Genome medicine
  • [ISO-abbreviation] Genome Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2873797
  •  go-up   go-down


44. Prensner JR, Chinnaiyan AM: Oncogenic gene fusions in epithelial carcinomas. Curr Opin Genet Dev; 2009 Feb;19(1):82-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncogenic gene fusions in epithelial carcinomas.
  • New discoveries regarding recurrent chromosomal aberrations in epithelial tumors have challenged the view that gene fusions play a minor role in these cancers.
  • This work has generated new insights into the molecular subtypes of tumors and highlighted important advances in bioinformatics, sequencing, and microarray technology as tools for gene fusion discovery.
  • Nevertheless, the majority of chromosomal abnormalities in epithelial cancers remain uncharacterized, underscoring the limitations of our knowledge of carcinogenesis and the requirement for further research.

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • SciCrunch. KEGG: Data: Disease Annotation .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):157-65 [18000366.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Oncogene. 2008 Jan 10;27(3):253-63 [17637754.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] PLoS Comput Biol. 2008 Apr;4(4):e1000051 [18404202.001]
  • [Cites] Mod Pathol. 2008 May;21 Suppl 2:S37-43 [18437172.001]
  • [Cites] Nat Genet. 2008 Jun;40(6):685-6 [18509307.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3380-5 [18519767.001]
  • [Cites] Clin Cancer Res. 2008 Jun 1;14(11):3395-400 [18519769.001]
  • [Cites] J Natl Cancer Inst. 2008 Jun 4;100(11):815-25 [18505969.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4971-6 [18593892.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Genome Res. 2008 Jul;18(7):1143-9 [18326688.001]
  • [Cites] Science. 2008 Aug 15;321(5891):956-60 [18599741.001]
  • [Cites] Mod Pathol. 2008 Dec;21(12):1451-60 [18500259.001]
  • [Cites] Neoplasia. 2008 Feb;10(2):177-88 [18283340.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):177-83 [14993899.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):331-4 [15054488.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3634-41 [15077183.001]
  • [Cites] Cancer. 2004 Jun 1;100(11):2362-6 [15160339.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):732-8 [15238980.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13257-61 [15326299.001]
  • [Cites] Science. 1990 Feb 16;247(4944):824-30 [2406902.001]
  • [Cites] Science. 1990 Mar 2;247(4946):1079-82 [2408149.001]
  • [Cites] Science. 1991 Nov 29;254(5036):1371-4 [1720570.001]
  • [Cites] Nat Genet. 1997 Feb;15(2):170-4 [9020842.001]
  • [Cites] Clin Cancer Res. 1998 Jan;4(1):223-8 [9516975.001]
  • [Cites] Mod Pathol. 2008 Feb;21(2):67-75 [18065961.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):58-71 [12661006.001]
  • [Cites] Oncogene. 2003 Jul 17;22(29):4578-80 [12881714.001]
  • [Cites] Genes Chromosomes Cancer. 1998 Oct;23(2):81-99 [9739011.001]
  • [Cites] J Natl Cancer Inst. 1960 Jul;25:85-109 [14427847.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jan;90(1):463-8 [15483076.001]
  • [Cites] Semin Cancer Biol. 2005 Jun;15(3):224-35 [15826837.001]
  • [Cites] Clin Lab Med. 2005 Jun;25(2):363-78 [15848741.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Aug;43(4):350-66 [15880352.001]
  • [Cites] Science. 2005 Oct 28;310(5748):644-8 [16254181.001]
  • [Cites] Endocrinology. 2006 Jan;147(1):367-76 [16179407.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jan;91(1):213-20 [16219715.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Science. 2000 Aug 25;289(5483):1357-60 [10958784.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13808-13 [11717438.001]
  • [Cites] Am J Pathol. 2001 Dec;159(6):1987-92 [11733348.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4477-82 [11930005.001]
  • [Cites] Cancer Cell. 2002 Nov;2(5):367-76 [12450792.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):304-7 [12543779.001]
  • [Cites] Nat Genet. 2003 Feb;33(2):208-13 [12539049.001]
  • [Cites] Genes Chromosomes Cancer. 2006 Jul;45(7):717-9 [16575875.001]
  • [Cites] Neoplasia. 2006 Jun;8(6):465-9 [16820092.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8337-41 [16951139.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1082-91 [16936731.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1929-35 [17008526.001]
  • [Cites] Neoplasia. 2006 Oct;8(10):826-32 [17032499.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):277-83 [16832349.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):919-29 [17283122.001]
  • [Cites] Neoplasia. 2007 Feb;9(2):166-80 [17356713.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):882-8 [17527075.001]
  • [Cites] Neoplasia. 2007 May;9(5):443-54 [17534450.001]
  • [Cites] Oncogene. 2007 Jul 5;26(31):4596-9 [17237811.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):595-9 [17671502.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5103-8 [17785564.001]
  • [Cites] Cancer Res. 2007 Sep 1;67(17):7991-5 [17804708.001]
  • [Cites] J Cell Biochem. 2007 Oct 1;102(2):320-31 [17722107.001]
  • [Cites] J Clin Pathol. 2007 Nov;60(11):1238-43 [17259299.001]
  • (PMID = 19233641.001).
  • [ISSN] 1879-0380
  • [Journal-full-title] Current opinion in genetics & development
  • [ISO-abbreviation] Curr. Opin. Genet. Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA069568-110020; United States / NCI NIH HHS / CA / R01 CA132874; United States / NCI NIH HHS / CA / CA132874-01A1; United States / NCI NIH HHS / CA / CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568-06A10016; United States / NCI NIH HHS / CA / R01 CA132874-01A1; United States / NCI NIH HHS / CA / CA069568-110020; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / CA069568-06A10016; United States / NCI NIH HHS / CA / U01 CA111275-04; United States / NCI NIH HHS / CA / P50 CA069568; United States / NCI NIH HHS / CA / U01 CA111275
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion
  • [Number-of-references] 69
  • [Other-IDs] NLM/ NIHMS102222; NLM/ PMC2676581
  •  go-up   go-down


45. Mays MC: Basaloid epithelial tumors of dogs and cats. Vet Clin Pathol; 2010 Jun;39(2):133; author reply 133-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basaloid epithelial tumors of dogs and cats.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Vet Clin Pathol. 2010 Mar;39(1):96-8 [19645743.001]
  • (PMID = 20624263.001).
  • [ISSN] 1939-165X
  • [Journal-full-title] Veterinary clinical pathology
  • [ISO-abbreviation] Vet Clin Pathol
  • [Language] ENG
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  •  go-up   go-down


46. Zhu Y, Nilsson M, Sundfeldt K: Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro. Endocrinology; 2010 Nov;151(11):5497-505
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phenotypic plasticity of the ovarian surface epithelium: TGF-beta 1 induction of epithelial to mesenchymal transition (EMT) in vitro.
  • Ovarian surface epithelium (OSE) is the most conceivable cell origin of epithelial ovarian carcinomas.
  • Unlike many other epithelial tumors, the precancerous lesion acquires expression of epithelial markers, e.g.
  • E-cadherin and claudins, suggesting that OSE cells undergo mesenchymal to epithelial transition (MET) during transformation.
  • Recent findings indicate that TGF-β1, a prototypic stimulus of epithelial to mesenchymal transition (EMT), i.e. reverse to MET, is produced at significant amounts in the intact ovary.
  • In the present study, we therefore investigated whether TGF-β1 changes the OSE phenotype accordingly, focusing on epithelial junction proteins and transcriptional EMT regulators quantified by real-time RT-PCR and Western blotting in cultured normal human OSE.
  • Early OSE passages were found to paradoxically express de novo E-cadherin and also establish tight junctions exhibiting claudin-1 (but not claudin-3 and -4) and occludin.
  • Stimulation with TGF-β1 (100 ng/ml) for 3-5 d down-regulated all these epithelial markers including Crumbs3 and also prevented the formation of an epithelial barrier This was accompanied by sustained expression of Snail and N-cadherin and transient expression of Slug, whereas Zeb1 (zinc finger E-box binding homeobox 1) and Twist mRNA levels were not significantly changed.
  • In conclusion, TGF-β1 enforces the mesenchymal phenotype of OSE cells in vitro by an EMT-like process, leading to an altered molecular composition of the epithelial junction complex that partly coincides with the expression pattern of the native OSE.
  • This suggests a potential role of TGF-β1-induced EMT in OSE under physiological conditions and possibly also in epithelial ovarian tumorigenesis.


47. Soltermann A, Tischler V, Arbogast S, Braun J, Probst-Hensch N, Weder W, Moch H, Kristiansen G: Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer. Clin Cancer Res; 2008 Nov 15;14(22):7430-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of epithelial-mesenchymal and mesenchymal-epithelial transition protein expression in non-small cell lung cancer.
  • PURPOSE: In carcinomas, invasive tumor growth is accompanied by desmoplastic stroma reaction and facilitated by epithelial-mesenchymal transition (EMT) of cancer cells.
  • We investigated the prognostic significance of the EMT indicator proteins periostin and vimentin in comparison with versican, a putative indicator of the opposite mechanism mesenchymal-epithelial transition (MET), and to the desmoplasia proteins collagen and elastin in non-small cell lung cancer (NSCLC).
  • EXPERIMENTAL DESIGN: Tumor of 533 patients with surgically resected NSCLC was used for analysis of stromal and epithelial protein expression by immunohistochemistry (EMT-MET proteins) and Elastica van Gieson histochemical staining (collagen and elastin).
  • High expression of periostin in either stroma or tumor epithelia, independently scored by two pathologists, correlated with male gender, higher stage, higher pT category, and larger tumor size, and in only stroma with tumor relapse.
  • High expression of versican in either stroma or epithelia as well as of stromal collagen had fewer but concordant associations with advanced tumor and periostin, respectively.
  • CONCLUSIONS: Because up-regulation is frequently observed in the stromal and epithelial tumor compartment, EMT-MET indicator proteins may be integrated in progression models of NSCLC.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / metabolism. Cell Adhesion Molecules / biosynthesis. Lung Neoplasms / metabolism. Vimentin / biosynthesis
  • [MeSH-minor] Age Factors. Aged. Cell Differentiation / physiology. Collagen / biosynthesis. Elastin / biosynthesis. Epithelial Cells / metabolism. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Mesoderm / metabolism. Middle Aged. Prognosis. Sex Factors. Tissue Array Analysis. Versicans / biosynthesis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19010860.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / POSTN protein, human; 0 / Vimentin; 126968-45-4 / Versicans; 9007-34-5 / Collagen; 9007-58-3 / Elastin
  •  go-up   go-down


48. Hashimoto Y, Ito T, Inoue H, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M, Shimada Y: Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res; 2005 Apr 1;11(7):2597-605
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of fascin in epithelial neoplasms has been described only recently, and the role of fascin in esophageal squamous cell carcinoma (ESCC) is still unknown.
  • RESULTS: In immunohistochemical study, the intensity of fascin expression was usually increased in the tumor compared with that in normal epithelium.
  • The fascin immunoreactive rate was associated with extent of the tumor (P = 0.002) and lymph node metastasis (P = 0.003).
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carrier Proteins / genetics. Esophageal Neoplasms / pathology. Microfilament Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blotting, Western. Cell Line, Tumor. Cell Movement. Down-Regulation. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis. Transfection

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814639.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 146808-54-0 / fascin
  •  go-up   go-down


49. Hill SC, Youde SJ, Man S, Teale GR, Baxendale AJ, Hislop A, Davies CC, Luesley DM, Blom AM, Rickinson AB, Young LS, Eliopoulos AG: Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol; 2005 Jan 1;174(1):41-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, CD154 treatment of carcinoma cells expressing proteasome-dependent but TAP-independent Ags from the EBV-encoded BRLF1 and BMLF1 failed to increase tumor cell lysis by specific CTLs.
  • Taken together, these observations demonstrate the functional expression of CD40 in epithelial tumors of the cervix and support the clinical exploitation of the CD40 pathway for the treatment of cervical cancer through its multiple effects on tumor cell growth, apoptosis, and immune recognition.
  • [MeSH-major] Antigens, CD40 / metabolism. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Apoptosis / drug effects. T-Lymphocytes, Cytotoxic / immunology. Uterine Cervical Neoplasms / immunology. Uterine Cervical Neoplasms / metabolism
  • [MeSH-minor] Antigen Presentation / drug effects. Antigen Presentation / immunology. CD40 Ligand / metabolism. Carcinoma, Squamous Cell / immunology. Carcinoma, Squamous Cell / metabolism. Cervical Intraepithelial Neoplasia / immunology. Cervical Intraepithelial Neoplasia / metabolism. Female. Flow Cytometry. HeLa Cells. Humans. Immunoblotting. Immunohistochemistry. Mitogen-Activated Protein Kinase Kinases / drug effects. Mitogen-Activated Protein Kinase Kinases / metabolism. NF-kappa B / drug effects. NF-kappa B / metabolism. Papillomavirus Infections. Proteasome Endopeptidase Complex / drug effects. Proteasome Endopeptidase Complex / immunology. Signal Transduction / drug effects. Signal Transduction / immunology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15611226.001).
  • [ISSN] 0022-1767
  • [Journal-full-title] Journal of immunology (Baltimore, Md. : 1950)
  • [ISO-abbreviation] J. Immunol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD40; 0 / NF-kappa B; 147205-72-9 / CD40 Ligand; EC 2.7.12.2 / Mitogen-Activated Protein Kinase Kinases; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  •  go-up   go-down


50. Tapia B, Ahrens W, Kenney B, Touloukian R, Reyes-Múgica M: Acinar cell carcinoma versus solid pseudopapillary tumor of the pancreas in children: a comparison of two rare and overlapping entities with review of the literature. Pediatr Dev Pathol; 2008 Sep-Oct;11(5):384-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acinar cell carcinoma versus solid pseudopapillary tumor of the pancreas in children: a comparison of two rare and overlapping entities with review of the literature.
  • Primary epithelial tumors of the pancreas are extremely uncommon in children, and among these, acinar cell carcinoma (ACC) is the most rare.
  • Despite its rarity, ACC should be kept in the differential diagnosis of pediatric pancreatic exocrine tumors.
  • We also provide a comparison with an example of solid pseudopapillary tumor, another relatively infrequent epithelial tumor of the pancreas in the young.
  • We review the relevant literature addressing the clinical and pathologic features of ACC and its distinction from other pancreatic neoplasms.
  • [MeSH-major] Carcinoma, Acinar Cell / diagnosis. Carcinoma, Acinar Cell / pathology. Pancreatic Cyst / pathology. Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19006424.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / SERPINA1 protein, human; 0 / alpha 1-Antitrypsin
  • [Number-of-references] 37
  •  go-up   go-down


51. Motokura T, Nakamura Y, Sato H: Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies. BMC Cancer; 2007;7:217
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant overexpression of an epithelial marker, 14-3-3sigma, in a subset of hematological malignancies.
  • BACKGROUND: 14-3-3sigma is a p53-mediated cell-cycle inhibitor in epithelial cells.
  • The expression of 14-3-3sigma is frequently altered in cancers of epithelial origin associated with altered DNA methylation.
  • Since its involvement in a non-epithelial tumor is unknown, we examined 14-3-3sigma expression in patients with haematological malignancies.
  • In contrast to epithelial tumors, methylation status of the 14-3-3sigma gene was not associated with expression in hematological malignancies.
  • The expression levels of 14-3-3sigma, CDKN2A and ARF were not correlated with but rather reciprocal to one another, suggesting that simultaneous overexpression of any two of them is incompatible with tumor growth.
  • CONCLUSION: 14-3-3sigma, an epithelial cell marker, was overexpressed significantly in a subset of mature lymphoid malignancies.
  • This is the first report of aberrant 14-3-3sigma expression in non-epithelial tumors in vivo.
  • Since the significance of 14-3-3sigma overexpression is unknown even in epithelial tumors such as pancreatic cancers, further analysis of regulation and function of the 14-3-3sigma gene in non-epithelial as well as epithelial tumors is warranted.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Exonucleases / biosynthesis. Hematologic Neoplasms / genetics. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] 14-3-3 Proteins. ADP-Ribosylation Factors / genetics. Base Sequence. Blotting, Western. Cell Cycle. DNA Methylation. Exoribonucleases. Gene Expression Regulation, Neoplastic / genetics. Genes, p16. Humans. Polymorphism, Single-Stranded Conformational / genetics. RNA, Messenger / biosynthesis. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / genetics. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 1999 Nov;13(11):1760-9 [10557050.001]
  • [Cites] Neurosci Res. 2006 Sep;56(1):61-72 [16797759.001]
  • [Cites] J Cell Biol. 2000 May 29;149(5):1117-30 [10831615.001]
  • [Cites] Oncogene. 2000 Nov 2;19(46):5298-302 [11077447.001]
  • [Cites] Oncogene. 2001 Jun 7;20(26):3348-53 [11423985.001]
  • [Cites] J Biol Chem. 2001 Nov 30;276(48):45201-6 [11574543.001]
  • [Cites] Blood. 2002 Feb 15;99(4):1411-8 [11830494.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2072-6 [11929827.001]
  • [Cites] Oncogene. 2002 Apr 4;21(15):2418-24 [11948426.001]
  • [Cites] Nature. 2002 Jun 20;417(6891):871-5 [12075357.001]
  • [Cites] Oncogene. 2002 May 2;21(19):3043-9 [12082535.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):165-9 [12582028.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • [Cites] Cancer Lett. 2003 Oct 28;200(2):161-6 [14568170.001]
  • [Cites] Nat Rev Cancer. 2003 Dec;3(12):931-43 [14737123.001]
  • [Cites] Biochem J. 2004 Jul 15;381(Pt 2):329-42 [15167810.001]
  • [Cites] Carcinogenesis. 2004 Sep;25(9):1575-85 [15073049.001]
  • [Cites] Anal Biochem. 1988 Apr;170(1):203-8 [3389511.001]
  • [Cites] Cell Growth Differ. 1992 Aug;3(8):507-13 [1390337.001]
  • [Cites] Lab Invest. 1993 Mar;68(3):361-6 [8450652.001]
  • [Cites] Cell. 1995 Dec 15;83(6):993-1000 [8521522.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Blood. 1997 Feb 1;89(3):965-74 [9028328.001]
  • [Cites] Cell. 1997 Nov 28;91(5):649-59 [9393858.001]
  • [Cites] Leukemia. 1998 Jun;12(6):845-59 [9639410.001]
  • [Cites] Leuk Res. 1998 May;22(5):413-20 [9652727.001]
  • [Cites] Mol Cell. 1997 Dec;1(1):3-11 [9659898.001]
  • [Cites] Nature. 1999 Oct 7;401(6753):616-20 [10524633.001]
  • [Cites] Amino Acids. 2005 Mar;28(2):199-205 [15723242.001]
  • [Cites] Pathol Int. 2005 Nov;55(11):707-15 [16271083.001]
  • [Cites] Int J Cancer. 2006 May 15;118(10):2448-54 [16353156.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3248-55 [16540677.001]
  • [Cites] Cancer Lett. 2006 May 8;236(1):105-14 [15979784.001]
  • [Cites] Semin Cancer Biol. 2006 Jun;16(3):162-72 [16678438.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 May 23;97(11):6049-54 [10811911.001]
  • (PMID = 18036248.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 14-3-3 Proteins; 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53; EC 3.1.- / Exonucleases; EC 3.1.- / Exoribonucleases; EC 3.1.- / SFN protein, human; EC 3.6.5.2 / ADP-Ribosylation Factors
  • [Other-IDs] NLM/ PMC2222637
  •  go-up   go-down


52. Mega S, Oguri M, Kawasaki R, Hazama K, Iwai K, Kondo S: Large-cell neuroendocrine carcinoma in the thymus. Gen Thorac Cardiovasc Surg; 2008 Nov;56(11):566-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Large-cell neuroendocrine carcinoma in the thymus is a rare cancer that is more aggressive and leads to a poorer prognosis than other thymic epithelial tumors.
  • [MeSH-major] Carcinoma, Neuroendocrine. Thymus Neoplasms
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Fatal Outcome. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy Dosage. Thymectomy. Thymus Gland / pathology. Time Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2006 Jun;54(6):256-9 [16813109.001]
  • [Cites] Semin Diagn Pathol. 1991 Feb;8(1):35-51 [1646476.001]
  • [Cites] Chest. 2003 Jul;124(1):141-6 [12853516.001]
  • [Cites] Histopathology. 1997 Sep;31(3):274-6 [9354899.001]
  • [Cites] Cancer. 2002 Jun 15;94(12):3115-9 [12115342.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2485-92 [7296496.001]
  • [Cites] Am J Surg Pathol. 1991 Jun;15(6):529-53 [1709558.001]
  • [Cites] Am J Clin Pathol. 2000 Jul;114(1):100-10 [10884805.001]
  • (PMID = 19002759.001).
  • [ISSN] 1863-6705
  • [Journal-full-title] General thoracic and cardiovascular surgery
  • [ISO-abbreviation] Gen Thorac Cardiovasc Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


53. Okumura M, Shiono H, Inoue M, Tanaka H, Yoon HE, Nakagawa K, Matsumura A, Ohta M, Iuchi K, Matsuda H: Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system. J Surg Oncol; 2007 Jan 1;95(1):40-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of surgical treatment for recurrent thymic epithelial tumors with reference to world health organization histologic classification system.
  • BACKGROUND AND OBJECTIVES: The aim of this study was to clarify the significance of surgical treatment for recurrent thymic epithelial tumors with reference to the World Health Organization (WHO) histological classification system.
  • PATIENTS: Among 67 patients with tumor recurrence, 22 underwent a re-resection.
  • There were 1 patient with a type AB tumor, 5 with type B1 tumors, 10 with type B2 tumors, 5 with type B3 tumors, and 1 with a carcinoma.
  • The average intervals from the initial resection to re-resection were 10.3, 7.8, 6.0, 2.4, and 2.6 years for patients with type AB, B1, B2, B3 tumors, and carcinoma, respectively.
  • The patient with a type AB tumor was alive at 2.4 years after re-resection, 12.7 years after the initial resection.
  • The 5-year survival rates following re-resection in the patients with type B1, B2, and B3 tumors were 100, 56, and 60, respectively.
  • The patient with a carcinoma died as a result of the tumor 2 years after re-resection.
  • CONCLUSION: WHO histological classification indicates the outcome of surgical treatment for recurrent thymic epithelial tumors.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Thymoma / classification. Thymoma / surgery. Thymus Neoplasms / classification. Thymus Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Humans. Middle Aged. Neoplasm Staging. Reoperation. Survival Rate. Treatment Outcome. World Health Organization

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192865.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Sumida A, Yanai H, Tanioka Y, Sakaguchi E, Yutoku K: Stenosis of gastric body as a rare complication after endoscopic submucosal dissection for multiple gastric epithelial tumors. J Gastrointest Cancer; 2008;39(1-4):34-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stenosis of gastric body as a rare complication after endoscopic submucosal dissection for multiple gastric epithelial tumors.
  • [MeSH-major] Gastric Mucosa / surgery. Gastric Outlet Obstruction / etiology. Gastroscopy. Neoplasms, Glandular and Epithelial / surgery. Postoperative Complications / etiology. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):771-7 [15557953.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2006 Aug;16(4):237-41 [16921303.001]
  • [Cites] J Gastroenterol. 2006 Oct;41(10):929-42 [17096062.001]
  • [Cites] Gastrointest Endosc. 2008 May;67(6):979-83 [18440388.001]
  • (PMID = 19294537.001).
  • [ISSN] 1941-6628
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline epithelial tumors of the ovary.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • Typically, borderline tumors are noninvasive neoplasms that have nuclear abnormalities and mitotic activity intermediate between benign and malignant tumors of similar cell type.
  • Borderline tumors of all surface epithelial cell types have been studied.
  • The most common and best understood are serous borderline tumors and mucinous borderline tumors of intestinal type, which are the subject of this review.
  • Some of the most challenging issues for serous tumors include: the criteria and clinical behavior of stromal microinvasion; the high prevalence of synchronous extraovarian disease; the classification and histopathologic features of associated peritoneal tumor implants, especially invasive implants; and, the prognostic significance of micropapillary tumors.
  • The mucinous borderline tumors of intestinal type have a different set of considerations, including: their frequently heterogeneous composition with coexisting benign, borderline and malignant elements; the classification and significance of accompanying noninvasive carcinoma; the recognition of stromal invasion, including microinvasion and expansile invasion; and, the historically misunderstood relationship to pseudomyxoma peritonei.
  • All of these issues are discussed in this presentation, as are the important gross and microscopic features of serous and mucinous borderline tumors and pertinent information on their treatment and prognosis.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


56. Ranson M, Shaw H, Wolf J, Hamilton M, McCarthy S, Dean E, Reid A, Judson I: A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin. Cancer Chemother Pharmacol; 2010 May;66(1):53-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I dose-escalation and bioavailability study of oral and intravenous formulations of erlotinib (Tarceva, OSI-774) in patients with advanced solid tumors of epithelial origin.
  • This study sought to determine the maximum tolerated dose (MTD) of erlotinib administered as a single 30-min infusion in patients with advanced solid tumors and absolute bioavailability of erlotinib tablets at matched doses.
  • [MeSH-major] Neoplasms, Glandular and Epithelial / drug therapy. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage
  • [MeSH-minor] Administration, Oral. Adolescent. Adult. Aged. Biological Availability. Dose-Response Relationship, Drug. Drug Administration Schedule. Erlotinib Hydrochloride. Female. Humans. Infusions, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Metastasis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19956953.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


57. Singer SR, Mupparapu M, Philipone E: Cone beam computed tomography findings in a case of plexiform ameloblastoma. Quintessence Int; 2009 Sep;40(8):627-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastoma is a fairly common and highly aggressive odontogenic tumor of epithelial origin.
  • [MeSH-major] Ameloblastoma / radiography. Mandibular Neoplasms / radiography. Odontogenic Tumors / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19639086.001).
  • [ISSN] 1936-7163
  • [Journal-full-title] Quintessence international (Berlin, Germany : 1985)
  • [ISO-abbreviation] Quintessence Int
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Magnata Filho LA, Bordallo MA, Pessoa CH, Corbo R, Bulzico DA, Dias FL, Machado AL, Soares AB, Ferman S: Thyroid spindle epithelial tumor with thymus-like differentiation (SETTLE): case report and review. Arq Bras Endocrinol Metabol; 2010 Oct;54(7):657-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thyroid spindle epithelial tumor with thymus-like differentiation (SETTLE): case report and review.
  • Spindle epithelial tumor with thymus-like element (SETTLE) is a rare malignant neoplasm of the thyroid, occurring predominantly in children, adolescents, and young adults.
  • Microscopic exam revealed a nodular, highly cellular neoplasm displayed in the classic biphasic pattern, with mixture of prominent spindle cell component and a minor glandular component lined by mucinous or respiratory-type epithelium.
  • [MeSH-major] Carcinoma / pathology. Neoplasms, Glandular and Epithelial / pathology. Thymus Gland / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21085772.001).
  • [ISSN] 1677-9487
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Brazil
  •  go-up   go-down


59. Höinghaus R, von Wasielewski R, Hewicker-Trautwein M, Freund M, Mischke R: Immunocytological detection of lymph node metastases in dogs with malignant epithelial tumours. J Comp Pathol; 2007 Jul;137(1):1-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunocytological detection of lymph node metastases in dogs with malignant epithelial tumours.
  • Cytological touch imprints of 161 lymph nodes from 72 dogs, as well as 50 fine needle aspirates from 23 dogs, with malignant epithelial tumours were included in the study.
  • In addition, lymph node touch imprints from dogs with primary tumours that reacted positively with the specific anticytokeratins CK7 (n=104) and CK20 (n=20) were also labelled with CK7 and CK20.
  • The immunocytological detection of lymph node metastases with the broad spectrum anti-cytokeratin AE1/AE3 in imprint smears resulted in a significant increase in sensitivity (0.99 vs 0.88 [conventional stain]) and in negative predictive value (0.99 vs 0.85) (P<0.01; t-test).
  • Specificity (0.93 vs 0.88) and positive predictive value (0.95 vs 0.90) did not differ significantly between the two techniques.
  • Immunolabelling with KL1 was associated with lower sensitivity and negative predictive value, indicating lack of cross-reactivity of this antibody with canine epithelial cells.
  • The study indicated the value of immunocytological labelling for the detection of metastases in cytological specimens of canine lymph node preparations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17543325.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Keratin-20; 0 / Keratin-7
  •  go-up   go-down


60. Yaris N, Nas Y, Cobanoglu U, Yavuz MN: Thymic carcinoma in children. Pediatr Blood Cancer; 2006 Aug;47(2):224-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thymic epithelial neoplasms consist of thymomas, thymic carcinoids, and thymic carcinomas.
  • Carcinomas are malignant tumors of the thymus characterized by obvious cytological anaplasia.
  • They constitute only 4%-14% of thymic epithelial neoplams.
  • [MeSH-major] Thymoma. Thymus Neoplasms

  • MedlinePlus Health Information. consumer health - Thymus Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007580.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 23
  •  go-up   go-down


61. Kim JY, Kim HO, Kim JS, Moon DH, Kim YH, Kim DK, Park SI, Park YS, Ryu JS: (18)F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic Epithelial Tumors. Nucl Med Mol Imaging; 2010 Sep;44(3):177-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] (18)F-FDG PET/CT is Useful for Pretreatment Assessment of the Histopathologic Type of Thymic Epithelial Tumors.
  • PURPOSE: This study was performed to assess the usefulness of (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) or PET/computed tomography (CT) for distinguishing thymic epithelial tumors according to World Health Organization (WHO) classifications.
  • METHODS: We analyzed a total of 45 patients (range, 29-75 years of age; mean, 55 years) with pathologically confirmed thymic epithelial tumors who underwent pretreatment (18)F-FDG PET or PET/CT between November 2003 and October 2009.
  • The size, visual grading of uptake value, peak standardized uptake value (SUVpeak), uptake pattern, and contour of each tumor, and associated findings on PET or PET/CT, were analyzed relative to the three simplified WHO subgroups: less-invasive thymomas (types A and AB), more-invasive thymomas (types B1, B2, and B3) and thymic carcinomas.
  • The visual grading scale (p < 0.000), uptake pattern (p = 0.001), and contour (p < 0.000) of the tumors differed significantly among the three simplified subgroups.
  • Pre-treatment evaluation with (18)F-FDG PET or PET/CT might be helpful in differentiating subgroups of thymic epithelial tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24899947.001).
  • [ISSN] 1869-3474
  • [Journal-full-title] Nuclear medicine and molecular imaging
  • [ISO-abbreviation] Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4042935
  • [Keywords] NOTNLM ; 18F-fluorodeoxyglucose / PET / Thymic carcinoma / Thymoma / Thymus
  •  go-up   go-down


62. Muangnoi P, Lu M, Lee J, Thepouyporn A, Mirzayans R, Le XC, Weinfeld M, Changbumrung S: Cytotoxicity, apoptosis and DNA damage induced by Alpinia galanga rhizome extract. Planta Med; 2007 Jul;73(8):748-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was conducted to analyze the capacity of galangal extract to induce cytotoxicity and DNA damage in six different human cell lines including normal and p53-inactive fibroblasts, normal epithelial and tumour mammary cells and a lung adenocarcinoma cell line.
  • There was no evidence for preferential cytotoxicity of tumour cells, but there was an indication that p53-active cell lines may be more sensitive than their p53-inactive counterparts.
  • [MeSH-minor] Breast / cytology. Cell Line, Tumor / drug effects. Epithelial Cells / drug effects. Fibroblasts / drug effects. Humans. Rhizome

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611930.001).
  • [ISSN] 0032-0943
  • [Journal-full-title] Planta medica
  • [ISO-abbreviation] Planta Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Plant Extracts
  •  go-up   go-down


63. Irazoqui FJ, Sendra VG, Lardone RD, Nores GA: Immune response to Thomsen-Friedenreich disaccharide and glycan engineering. Immunol Cell Biol; 2005 Aug;83(4):405-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Epithelial tumour cells typically show overexpression of the uncovered Gal(beta)1-3GalNAc(alpha)-O-Ser/Thr (Core 1) structure, known as the T antigen or the Thomsen-Friedenreich antigen, the oligosaccharide chain of which is called the Thomsen-Friedenreich disaccharide (TFD).
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / chemistry. Antigens, Tumor-Associated, Carbohydrate / immunology. Disaccharides / chemistry. Disaccharides / immunology. Drug Design. Polysaccharides / chemistry. Polysaccharides / immunology
  • [MeSH-minor] Animals. Carbohydrate Conformation. Neoplasms / chemistry. Neoplasms / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16033536.001).
  • [ISSN] 0818-9641
  • [Journal-full-title] Immunology and cell biology
  • [ISO-abbreviation] Immunol. Cell Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Disaccharides; 0 / Polysaccharides; 3554-90-3 / Thomsen-Friedenreich antigen
  •  go-up   go-down


64. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D: The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther; 2006 Feb;13(2):115-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.
  • Recent studies are reviewed indicating that the transcription factor early growth response-1 (Egr1) is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin.
  • It is suggested that these defects in the suppressor network allow for the unopposed induction of TGFbeta1 and fibronectin, which favor transformation and survival of prostate tumor epithelial cells, and explain the role of Egr1 in prostate cancer.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Carcinogenesis. 1994 Aug;15(8):1667-74 [8055649.001]
  • [Cites] Mol Endocrinol. 1994 May;8(5):595-602 [8058069.001]
  • [Cites] Oncogene. 1995 Feb 2;10(3):467-75 [7845671.001]
  • [Cites] J Biol Chem. 1995 Dec 1;270(48):28623-8 [7499379.001]
  • [Cites] Hereditas. 1995;122(3):239-43 [8537239.001]
  • [Cites] Semin Oncol. 1999 Aug;26(4):382-98 [10482181.001]
  • [Cites] J Cell Biochem. 2005 Jan 1;94(1):117-25 [15517593.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9002-11 [15604265.001]
  • [Cites] Cancer Gene Ther. 2005 Jul;12(7):655-62 [15818381.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5133-43 [15958557.001]
  • [Cites] Curr Opin Cell Biol. 2001 Oct;13(5):555-62 [11544023.001]
  • [Cites] Mol Cell. 2001 Aug;8(2):317-25 [11545734.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2788-96 [11555594.001]
  • [Cites] Cancer Biochem Biophys. 1995 Nov;15(2):107-10 [8590435.001]
  • [Cites] Methods Mol Biol. 2000;142:55-65 [10806613.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(14):5261-8 [10866682.001]
  • [Cites] J Biol Chem. 2000 Jul 7;275(27):20315-23 [10783396.001]
  • [Cites] Biotechniques. 2000 Jul;29(1):162-9 [10907091.001]
  • [Cites] J Biol Chem. 2000 Aug 11;275(32):24565-74 [10835423.001]
  • [Cites] Exp Cell Res. 2000 Aug 25;259(1):149-57 [10942587.001]
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3522-9 [10999739.001]
  • [Cites] Cancer Genet Cytogenet. 1995 Mar;80(1):47-54 [7697632.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5545-9 [7777546.001]
  • [Cites] Oncogene. 1995 Oct 5;11(7):1261-9 [7478546.001]
  • [Cites] J Urol. 1996 Mar;155(3):975-81 [8583621.001]
  • [Cites] Science. 1996 Aug 30;273(5279):1219-21 [8703054.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4541-6 [8813154.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11831-6 [8876223.001]
  • [Cites] J Biol Chem. 1996 Nov 15;271(46):29231-7 [8910582.001]
  • [Cites] Crit Rev Oncog. 1996;7(1-2):101-25 [9109500.001]
  • [Cites] Int J Cancer. 1997 Jul 3;72(1):102-9 [9212230.001]
  • [Cites] J Biol Chem. 1997 Aug 8;272(32):20131-8 [9242687.001]
  • [Cites] Cancer Gene Ther. 1998 Jan-Feb;5(1):3-28 [9476963.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5246-50 [9560261.001]
  • [Cites] Cancer Res. 1998 Jun 1;58(11):2461-8 [9622090.001]
  • [Cites] Am J Respir Cell Mol Biol. 1998 Jun;18(6):823-33 [9618387.001]
  • [Cites] J Biol Chem. 1999 Feb 12;274(7):4400-11 [9933644.001]
  • [Cites] EMBO J. 1999 Mar 1;18(5):1345-56 [10064600.001]
  • [Cites] Cytokine. 1999 Feb;11(2):157-62 [10089138.001]
  • [Cites] Cell Death Differ. 1998 Jan;5(1):96-106 [10200450.001]
  • [Cites] Adv Cancer Res. 1999;76:1-20 [10218097.001]
  • [Cites] J Pathol. 1999 Jan;187(1):82-90 [10341708.001]
  • [Cites] Int Immunol. 1999 Jun;11(6):871-9 [10360960.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):173-93 [12085961.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1433-44 [12168820.001]
  • [Cites] Trends Biochem Sci. 2002 Sep;27(9):462-7 [12217521.001]
  • [Cites] Exp Mol Pathol. 2002 Oct;73(2):142-53 [12231217.001]
  • [Cites] J Cell Biochem. 2003 Jan 1;88(1):138-43 [12461783.001]
  • [Cites] Biochem J. 2003 Mar 15;370(Pt 3):1019-25 [12457461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 18;100(6):3233-8 [12629205.001]
  • [Cites] Cell Struct Funct. 2003 Feb;28(1):11-21 [12655146.001]
  • [Cites] J Biol Chem. 2003 Apr 4;278(14):11802-10 [12556466.001]
  • [Cites] Oncogene. 2003 Jul 3;22(27):4194-204 [12833142.001]
  • [Cites] Biochem J. 2003 Aug 1;373(Pt 3):739-46 [12755686.001]
  • [Cites] Oncogene. 2003 Aug 14;22(34):5325-37 [12917634.001]
  • [Cites] Can J Urol. 2003 Aug;10(4):1924-33 [14503938.001]
  • [Cites] Oncogene. 2003 Nov 13;22(51):8246-54 [14614448.001]
  • [Cites] FASEB J. 2003 Dec;17(15):2316-8 [14525948.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50422-7 [14517213.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1002:197-216 [14751836.001]
  • [Cites] Mol Cancer Res. 2004 Jul;2(7):371-86 [15280445.001]
  • [Cites] J Exp Med. 2004 Aug 2;200(3):377-89 [15289506.001]
  • [Cites] Dev Biol. 2004 Sep 15;273(2):175-84 [15328005.001]
  • [Cites] Mol Cancer Ther. 2004 Sep;3(9):1167-75 [15367711.001]
  • [Cites] Endocrinology. 2004 Oct;145(10):4660-6 [15231710.001]
  • [Cites] Adv Exp Med Biol. 1992;324:107-14 [1492611.001]
  • [Cites] J Cell Biochem Suppl. 1992;16H:99-105 [1289680.001]
  • [Cites] Science. 1993 Apr 23;260(5107):536-9 [8475385.001]
  • [Cites] Genes Dev. 1994 Jan;8(1):9-22 [8288131.001]
  • [Cites] Biochem Biophys Res Commun. 1994 May 16;200(3):1271-6 [8185575.001]
  • [Cites] Cell. 1994 Jul 15;78(1):59-66 [8033212.001]
  • [Cites] Oncogene. 1999 Jun 17;18(24):3633-42 [10380885.001]
  • [Cites] Histochem Cell Biol. 1999 Jul;112(1):51-61 [10461812.001]
  • [Cites] J Am Soc Nephrol. 1999 Sep;10(9):1891-9 [10477140.001]
  • [Cites] Development. 1999 Nov;126(22):5061-71 [10529423.001]
  • [Cites] DNA Res. 1999 Oct 29;6(5):347-51 [10574463.001]
  • [Cites] J Clin Invest. 2000 Mar;105(5):653-62 [10712437.001]
  • [Cites] J Biol Chem. 2000 Dec 8;275(49):38524-31 [10984481.001]
  • [Cites] Nat Med. 2001 Jan;7(1):101-7 [11135623.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):863-70 [11251186.001]
  • [Cites] Hum Pathol. 2001 Sep;32(9):935-9 [11567222.001]
  • [Cites] Acta Oncol. 2001;40(6):735-8 [11765068.001]
  • [Cites] Nat Cell Biol. 2001 Dec;3(12):1124-8 [11781575.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5484-9 [11729185.001]
  • [Cites] Gene Ther. 2002 Apr;9(8):495-502 [11948374.001]
  • (PMID = 16138117.001).
  • [ISSN] 0929-1903
  • [Journal-full-title] Cancer gene therapy
  • [ISO-abbreviation] Cancer Gene Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102688-05; United States / NCI NIH HHS / CA / R01 CA102688; United States / NCI NIH HHS / CA / R01 CA084107-05; United States / NCI NIH HHS / CA / U01 CA084998-05; United States / NCI NIH HHS / CA / U01 CA084998; United States / NCI NIH HHS / CA / CA067888-17; United States / NCI NIH HHS / CA / CA084998-05; United States / NCI NIH HHS / CA / R01 CA102688-05; United States / PHS HHS / / R01 67888; United States / NCI NIH HHS / CA / 1R01 CA102688; United States / NCI NIH HHS / CA / UO1 CA084998; United States / NCI NIH HHS / CA / CA084107-05; United States / NCI NIH HHS / CA / R01 CA084107; United States / NCI NIH HHS / CA / R01 CA067888-17
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / EGR1 protein, human; 0 / Early Growth Response Protein 1; 0 / Fibronectins; 0 / Plasminogen Activator Inhibitor 1; 0 / TGFB1 protein, human; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 93
  • [Other-IDs] NLM/ NIHMS56346; NLM/ PMC2455793
  •  go-up   go-down


65. Fujishiro M: Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms. World J Gastroenterol; 2008 Jul 21;14(27):4289-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspective on the practical indications of endoscopic submucosal dissection of gastrointestinal neoplasms.
  • This technique is applied for the endoscopic treatment of epithelial neoplasms in the gastrointestinal tract from the pharynx to the rectum.
  • Furthermore, some carcinoids and submucosal tumors in the gastrointestinal tract are treated by ESD.
  • In this review, practical guidelines of ESD for the gastrointestinal neoplasms are discussed based on the evidence found in the literature.
  • [MeSH-major] Endoscopy / methods. Gastric Mucosa / pathology. Gastroenterology / methods. Gastrointestinal Neoplasms / diagnosis. Gastrointestinal Neoplasms / pathology. Medical Oncology / methods
  • [MeSH-minor] Algorithms. Carcinoid Tumor / diagnosis. Decision Support Techniques. Endoscopes, Gastrointestinal. Humans. Lymphatic Metastasis. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gut. 2006 Nov;55(11):1592-7 [16682427.001]
  • [Cites] Endoscopy. 2006 Oct;38(10):1024-8 [17058168.001]
  • [Cites] Gastrointest Endosc. 2004 Nov;60(5):703-10 [15557945.001]
  • [Cites] Gut. 2005 Feb;54(2):187-92 [15647178.001]
  • [Cites] Cancer. 2000 Mar 15;88(6):1285-93 [10717608.001]
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):697-700 [10840302.001]
  • [Cites] Gastrointest Endosc. 2000 Sep;52(3):328-32 [10968845.001]
  • [Cites] Gastrointest Endosc. 2001 Jul;54(1):62-6 [11427843.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):501-6 [11437043.001]
  • [Cites] Gastrointest Endosc. 2001 Dec;54(6):682-8 [11726842.001]
  • [Cites] Dig Liver Dis. 2002 Feb;34(2):137-40 [11926558.001]
  • [Cites] J Gastrointest Surg. 2001 Nov-Dec;5(6):588-93 [12086896.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):203-6 [12584637.001]
  • [Cites] Gastrointest Endosc. 2003 Apr;57(4):583-7 [12665777.001]
  • [Cites] Gastrointest Endosc. 2003 Jun;57(7):854-9 [12776032.001]
  • [Cites] J Clin Gastroenterol. 2003 Nov-Dec;37(5):381-6 [14564184.001]
  • [Cites] Gastrointest Endosc. 2003 Dec;58(6 Suppl):S3-43 [14652541.001]
  • [Cites] Gastric Cancer. 2003;6(4):255-61 [14716521.001]
  • [Cites] Gastric Cancer. 2003;6(4):262-6 [14716522.001]
  • [Cites] Endoscopy. 2004 Mar;36(3):202-5 [14986216.001]
  • [Cites] Hepatogastroenterology. 2004 Jan-Feb;51(55):269-72 [15011883.001]
  • [Cites] Endoscopy. 2004 Apr;36(4):306-12 [15057679.001]
  • [Cites] Gastric Cancer. 2005;8(1):42-6 [15747174.001]
  • [Cites] Gastroenterology. 2005 May;128(6):1717-51 [15887161.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3513-6 [16101171.001]
  • [Cites] Am J Surg. 2005 Sep;190(3):496-503 [16105543.001]
  • [Cites] Endoscopy. 2005 Sep;37(9):879-920 [16116544.001]
  • [Cites] World J Gastroenterol. 2005 Aug 28;11(32):5061-3 [16124067.001]
  • [Cites] Gastrointest Endosc. 2006 Jan;63(1):16-21 [16377310.001]
  • [Cites] Gastrointest Endosc. 2006 Dec;64(6):877-83 [17140890.001]
  • [Cites] Gastrointest Endosc. 2007 Jan;65(1):3-10 [17185072.001]
  • [Cites] Endoscopy. 2007 Jan;39(1):30-5 [17252457.001]
  • [Cites] Dig Liver Dis. 2007 Jun;39(6):566-71 [17382610.001]
  • [Cites] Endoscopy. 2007 May;39(5):423-7 [17354181.001]
  • [Cites] Endoscopy. 2007 May;39(5):418-22 [17516348.001]
  • [Cites] Gut. 2007 Jun;56(6):863-8 [17213340.001]
  • [Cites] Clin Gastroenterol Hepatol. 2007 Jun;5(6):678-83; quiz 645 [17466600.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] World J Gastroenterol. 2007 Jun 28;13(24):3311-5 [17659669.001]
  • [Cites] World J Gastroenterol. 2007 Jun 28;13(24):3316-22 [17659670.001]
  • [Cites] World J Gastroenterol. 2007 Jul 21;13(27):3657-61 [17659722.001]
  • [Cites] Dig Dis Sci. 2007 Oct;52(10):2796-9 [17394064.001]
  • [Cites] Gastrointest Endosc. 2007 Nov;66(5):966-73 [17524403.001]
  • [Cites] Br J Surg. 2007 Dec;94(12):1536-42 [17948864.001]
  • [Cites] World J Gastroenterol. 2008 May 21;14(19):2962-7 [18494043.001]
  • [Cites] Surg Endosc. 2008 Jul;22(7):1729-35 [18074180.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1226-32 [15233658.001]
  • [Cites] J Gastroenterol. 2004 Jun;39(6):534-43 [15235870.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2461-3 [15285046.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):782-7 [15326573.001]
  • [Cites] Endoscopy. 2004 Sep;36(9):788-801 [15326574.001]
  • [Cites] Am Surg. 1991 Jul;57(7):434-7 [2058850.001]
  • [Cites] J Clin Gastroenterol. 1995 Mar;20(2):168-71; discussion 71-2 [7769204.001]
  • [Cites] Digestion. 1995;56(6):455-62 [8536814.001]
  • [Cites] World J Surg. 1996 Feb;20(2):183-8 [8661815.001]
  • [Cites] Dis Colon Rectum. 1996 Nov;39(11):1308-14 [8918445.001]
  • [Cites] Surgery. 1998 Apr;123(4):432-9 [9551070.001]
  • [Cites] Gastrointest Endosc. 2006 Feb;63(2):243-9 [16427929.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Mar;4(3):343-8 [16527698.001]
  • [Cites] Gastrointest Endosc. 2006 May;63(6):776-82 [16650537.001]
  • [Cites] Endoscopy. 2006 Apr;38(4):391-4 [16680640.001]
  • [Cites] Clin Gastroenterol Hepatol. 2006 Jun;4(6):688-94 [16713746.001]
  • [Cites] Endoscopy. 2006 May;38(5):493-7 [16767585.001]
  • [Cites] World J Gastroenterol. 2006 Jul 7;12(25):4026-8 [16810752.001]
  • [Cites] Gastrointest Endosc. 2006 Aug;64(2):255-9; discussion 260-2 [16860078.001]
  • [Cites] World J Gastroenterol. 2006 Aug 28;12(32):5108-12 [16937520.001]
  • (PMID = 18666315.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC2731178
  •  go-up   go-down


66. Vera J, García MD, Marigil M, Abascal M, Lopez JI, Ligorred L: Biphasic synovial sarcoma of the abdominal wall. Virchows Arch; 2006 Sep;449(3):367-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Synovial sarcoma arising in the abdominal wall is a rare tumor.
  • The tumor was first thought to be a sarcoma arising from the omentum or mesentery.
  • During surgery, a large tumor was found attached to the inner surface of the abdominal wall and compressing the gastrointestinal tract.
  • On microscopic examination the tumor corresponded to a biphasic synovial sarcoma immunoreactive for cytokeratins (AE1/AE3, 7 and 19), epithelial membrane antigen and carcinoembryonic antigen in the epithelial tumor cells, for E-cadherin especially in their glandular structure, vimentin, CD99, and CD56 in the spindle cell component and for bcl-2 protein.
  • The tumor recurred at the same site, and clinical course progressed to death 3 months after the initial diagnosis.
  • [MeSH-major] Abdominal Neoplasms / pathology. Abdominal Wall / pathology. Carcinosarcoma / pathology. Sarcoma, Synovial / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Antigens, CD56 / analysis. Antigens, CD99. Biomarkers, Tumor / analysis. Cadherins / analysis. Carcinoembryonic Antigen / analysis. Cell Adhesion Molecules / analysis. Fatal Outcome. Humans. Keratins / analysis. Male. Neoplasm Recurrence, Local. Tomography, X-Ray Computed. Vimentin / analysis

  • Genetic Alliance. consumer health - Synovial sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2005 May;29(5):569-78 [15832079.001]
  • [Cites] Hum Pathol. 1995 May;26(5):474-80 [7750931.001]
  • [Cites] Int J Cancer. 1997 Sep 17;72(6):995-1002 [9378564.001]
  • [Cites] Am J Surg Pathol. 1998 Jun;22(6):673-82 [9630174.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1080-2 [7487412.001]
  • [Cites] Hum Pathol. 1984 Jul;15(7):615-21 [6204918.001]
  • [Cites] Mod Pathol. 1996 Jul;9(7):738-41 [8832556.001]
  • [Cites] Pathol Int. 1997 Sep;47(9):637-41 [9311017.001]
  • [Cites] J Pathol. 2000 Nov;192(3):342-50 [11054718.001]
  • [Cites] Br J Cancer. 2001 Aug 3;85(3):405-11 [11487273.001]
  • [Cites] Am J Surg Pathol. 2002 Nov;26(11):1434-40 [12409719.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):469-77 [8391380.001]
  • [Cites] Hum Mol Genet. 1995 Jun;4(6):1097-9 [7655467.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1679-80 [9400520.001]
  • [Cites] Acta Pathol Jpn. 1983 Jan;33(1):23-36 [6301209.001]
  • [Cites] Am J Surg Pathol. 1996 Jan;20(1):36-45 [8540607.001]
  • [Cites] Orbit. 2003 Dec;22(4):299-303 [14685906.001]
  • [Cites] Mod Pathol. 1998 Jan;11(1):65-71 [9556426.001]
  • [Cites] Cancer. 1965 May;18:613-27 [14278894.001]
  • [Cites] Ann Surg. 1968 Nov;168(5):928-30 [4300893.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):996-1008 [2428727.001]
  • [Cites] Ann Diagn Pathol. 1998 Dec;2(6):401-21 [9930576.001]
  • [Cites] Surgery. 1950 Dec;28(6):1047-84 [14787842.001]
  • [Cites] Histopathology. 2004 Sep;45(3):245-53 [15330802.001]
  • [Cites] Genes Chromosomes Cancer. 1991 Sep;3(5):338-45 [1665704.001]
  • [Cites] Cancer. 1975 Apr;35(4):1243-53 [163680.001]
  • [Cites] Br J Cancer. 1970 Sep;24(3):471-4 [4319939.001]
  • [Cites] Cancer. 1989 Jun 1;63(11):2182-5 [2541885.001]
  • [Cites] Cancer. 1993 Jul 15;72(2):478-85 [8100481.001]
  • [Cites] Am J Clin Pathol. 1982 Jun;77(6):686-91 [6283877.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1980;388(3):349-60 [6254240.001]
  • [Cites] Histopathology. 1998 Dec;33(6):508-13 [9870144.001]
  • [Cites] Mod Pathol. 1992 Jul;5(4):357-62 [1379714.001]
  • [Cites] Am J Surg Pathol. 2000 Aug;24(8):1087-96 [10935649.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):379-402 [1721748.001]
  • [Cites] Cancer. 1987 May 15;59(10):1810-4 [3828949.001]
  • [Cites] J Surg Oncol. 1981;18(4):335-44 [6275210.001]
  • [Cites] J Pathol. 1985 Sep;147(1):49-57 [2995626.001]
  • [Cites] Cancer. 1973 May;31(5):1247-55 [4705164.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23 (2):220-6 [9989850.001]
  • [Cites] Am J Clin Oncol. 2005 Jun;28(3):323-4 [15923809.001]
  • (PMID = 16855839.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD56; 0 / Antigens, CD99; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cadherins; 0 / Carcinoembryonic Antigen; 0 / Cell Adhesion Molecules; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


67. Jindal S, Vij V, Singhal D, Chaudhary A: Squamous cell carcinoma of stomach. Trop Gastroenterol; 2006 Apr-Jun;27(2):91-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric squamous cell carcinoma is a rare epithelial tumour.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Stomach Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Stomach carcinoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17089621.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


68. Johnson KA, Brown PH: Drug development for cancer chemoprevention: focus on molecular targets. Semin Oncol; 2010 Aug;37(4):345-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A review of solid tumor targets provides a manageable list of factors that are critical to cancer cell survival.
  • As such, these targets represent factors that are not only clinically relevant but also may play a critical role in early tumor development prior to the evolution of frank invasive malignancy.
  • Among solid tumors, the treatment of breast cancer with targeted drugs has a long record benchmarked by the initial US Food and Drug Administation (FDA) approval of tamoxifen for metastatic breast cancer treatment in 1977.
  • The focus of this review is the pharmacologic manipulation of targets within epithelial tumor cells and the implication of those targets for intervening to suppress and eliminate premalignant cells in human tissue.
  • One of these is the refinement of early phase prevention trials to identify drug targets in epithelial cells that are at demonstrated risk of evolving into cancer cells, ie, cells from a developmental niche in cancer ontogeny.
  • To the extent that this approach can be developed, it will allow for cancer risk reduction in a way that is analogous to the measurement of tumor response to treatment.
  • In addition to drug targets located in epithelial tumor cells, another list of malignancy-associated targets could be generated by considering targets in tumor-associated stromal and endothelial cells (eg, fibroblast growth factor [FGF], vascular endothelial growth factor [VEGF]), as well as targets related to a systemic reservoir of circulating cells that can be recruited to carcinogenic influence by inflammatory factors such as nuclear factor (NF)kappaB.
  • The complementarities of target-related processes within tumors cells, in the tumor microenvironment, and beyond suggests that there is great potential for multi-targeted approaches that may be more effective than single agents and also less prone to resistance.
  • As long as multiple agents can be used in combination for optimal effect with acceptable toxicity, the co-targeting of the epithelial cell compartment along with other compartments of oncogenic activity is expected to expand the dimensions of targeted prevention and enhance the overall opportunity to eliminate precancer or cells at risk of eventually transitioning to invasive cancer.
  • [MeSH-major] Anticarcinogenic Agents / therapeutic use. Drug Delivery Systems. Drug Design. Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010. Published by Elsevier Inc.
  • (PMID = 20816505.001).
  • [ISSN] 1532-8708
  • [Journal-full-title] Seminars in oncology
  • [ISO-abbreviation] Semin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticarcinogenic Agents
  • [Number-of-references] 112
  •  go-up   go-down


69. Jakab C, Halász J, Szász AM, Kiss A, Schaff Z, Rusvai M, Gálfi P, Kulka J: Expression of claudin-1, -2, -3, -4, -5 and -7 proteins in benign and malignant canine mammary gland epithelial tumours. J Comp Pathol; 2008 Nov;139(4):238-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudin-1, -2, -3, -4, -5 and -7 proteins in benign and malignant canine mammary gland epithelial tumours.
  • Claudins are tight junction proteins expressed by epithelial and endothelial cells.
  • These results suggest that loss or reduction of expression of claudin-1, -2, -5 and -7 may lead to cellular disorientation, detachment and invasion in canine mammary neoplasia.
  • [MeSH-major] Carcinoma / metabolism. Carcinoma / veterinary. Dog Diseases / metabolism. Mammary Neoplasms, Animal / metabolism. Membrane Proteins / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18848337.001).
  • [ISSN] 0021-9975
  • [Journal-full-title] Journal of comparative pathology
  • [ISO-abbreviation] J. Comp. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Membrane Proteins
  •  go-up   go-down


70. Pino V, Ramsauer VP, Salas P, Carothers Carraway CA, Carraway KL: Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells: role in reversal of contact inhibition. J Biol Chem; 2006 Sep 29;281(39):29411-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Membrane mucin Muc4 induces density-dependent changes in ERK activation in mammary epithelial and tumor cells: role in reversal of contact inhibition.
  • An analysis of the effects of Muc4 expression on ERK phosphorylation in mammary tumor and epithelial cells, which exhibit both adhesion-dependent growth and contact inhibition of growth, showed that the effects are density dependent, with opposing effects on proliferating cells and contact-inhibited cells.
  • Muc4-induced abrogation of contact inhibition may be an important mechanism by which tumors progress from an early, more benign state to invasiveness.
  • [MeSH-major] Breast Neoplasms / metabolism. Epithelial Cells / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Mucins / physiology
  • [MeSH-minor] Cadherins / metabolism. Cell Line, Tumor. Cell Proliferation. Enzyme Activation. Humans. Models, Biological. Mucin-4. Proto-Oncogene Proteins c-raf / metabolism. Receptor, ErbB-2 / metabolism. p38 Mitogen-Activated Protein Kinases / metabolism


71. Gould VE, Schmitt M, Vinokurova S, Reddy VB, Bitterman P, Alonso A, Gattuso P: Human papillomavirus and p16 expression in inverted papillomas of the urinary bladder. Cancer Lett; 2010 Jun 28;292(2):171-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inverted papillomas of the urinary bladder are epithelial tumors considered to be of benign nature.
  • We conclude that HPV does not play an indispensable role in the development of urinary bladder inverted papillomas and that overexpression of p16(Ink4a) does not correlate with HPV infection in these tumors.
  • [MeSH-major] Alphapapillomavirus / isolation & purification. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Papilloma / metabolism. Papilloma / virology. Urinary Bladder Neoplasms / metabolism. Urinary Bladder Neoplasms / virology

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20036459.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16
  •  go-up   go-down


72. Yan YG, Zhao G, Ma JP, Cai SR, Zhan WH: Effects of different Helicobacter pylori culture filtrates on growth of gastric epithelial cells. World J Gastroenterol; 2008 Jun 21;14(23):3745-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of different Helicobacter pylori culture filtrates on growth of gastric epithelial cells.
  • AIM: To study the effects of different Helicobacter pylori (H pylori) culture filtrates on growth of gastric epithelial cells.
  • Gastric epithelial cells were treated with the filtrates, and cell growth was determined by growth curve and flow cytometry.
  • DNA damage of gastric epithelial cells was measured by single-cell microgel electrophoresis.
  • RESULTS: Gastric epithelial cells proliferated actively when treated by CagA-gene-positive broth culture filtrates, and colony formation reached 40%.
  • CONCLUSION: CagA-positive filtrates enhance the changes in morphology and growth characteristics of human gastric epithelial tumor cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2004 Aug 1;10(15):2232-40 [15259072.001]
  • [Cites] J Clin Microbiol. 2004 Jun;42(6):2508-17 [15184428.001]
  • [Cites] Exp Cell Res. 1988 Mar;175(1):184-91 [3345800.001]
  • [Cites] N Engl J Med. 1991 Oct 17;325(16):1132-6 [1891021.001]
  • [Cites] IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241 [7715068.001]
  • [Cites] Mutat Res. 1996 Jun 12;363(2):89-96 [8676929.001]
  • [Cites] Digestion. 1996;57(5):299-304 [8886572.001]
  • [Cites] Am J Pathol. 1997 Sep;151(3):821-9 [9284831.001]
  • [Cites] Cancer Sci. 2004 Dec;95(12):977-83 [15596047.001]
  • [Cites] Int J Mol Med. 2005 Oct;16(4):741-5 [16142414.001]
  • [Cites] Korean J Gastroenterol. 2005 Sep;46(3):159-65 [16179834.001]
  • [Cites] J Exp Clin Cancer Res. 2005 Sep;24(3):337-45 [16270519.001]
  • [Cites] Lancet. 1993 May 29;341(8857):1359-62 [8098787.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4709-15 [17510398.001]
  • [Cites] J Pathol. 2007 Oct;213(2):140-51 [17724739.001]
  • [Cites] Cytogenet Genome Res. 2007;118(2-4):277-83 [18000381.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2007;21(6):921-45 [18070696.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):306-23 [18166359.001]
  • [Cites] J Dig Dis. 2008 Feb;9(1):20-6 [18251790.001]
  • [Cites] Acta Gastroenterol Latinoam. 2007 Dec;37(4):238-45 [18254262.001]
  • [Cites] J Clin Gastroenterol. 2008 Mar;42(3):279-83 [18223496.001]
  • [Cites] Gastroenterology. 2001 Oct;121(4):784-91 [11606491.001]
  • [Cites] J Biol Chem. 2002 Mar 1;277(9):6775-8 [11788577.001]
  • [Cites] Mol Microbiol. 2002 Feb;43(4):971-80 [11929545.001]
  • [Cites] Mol Cell. 2002 Oct;10(4):745-55 [12419219.001]
  • [Cites] J Biol Chem. 2003 Feb 7;278(6):3664-70 [12446738.001]
  • [Cites] J Cell Biol. 2003 Apr 28;161(2):249-55 [12719469.001]
  • [Cites] Gastroenterology. 2003 Dec;125(6):1636-44 [14724815.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Apr;13(4):631-7 [15066929.001]
  • [Cites] J Gastroenterol. 2004;39(2):97-103 [15069615.001]
  • [Cites] Gastroenterology. 2004 Aug;127(2):514-23 [15300584.001]
  • (PMID = 18595143.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Bacterial; 0 / Bacterial Proteins; 0 / Culture Media, Conditioned; 0 / cagA protein, Helicobacter pylori
  • [Other-IDs] NLM/ PMC2719239
  •  go-up   go-down


73. Schmalhofer O, Brabletz S, Brabletz T: E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev; 2009 Jun;28(1-2):151-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The embryonic program 'epithelial-mesenchymal transition' (EMT) is activated during tumor invasion in disseminating cancer cells.
  • In addition to an accumulation of cancer stem cells, nuclear beta-catenin induces a gene expression pattern favoring tumor invasion, and mounting evidence indicates multiple reciprocal interactions of E-cadherin and beta-catenin with EMT-inducing transcriptional repressors to stabilize an invasive mesenchymal phenotype of epithelial tumor cells.
  • [MeSH-major] Cadherins / metabolism. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / metabolism. Neoplasms / metabolism. Neoplasms / pathology. Transcription Factors / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Animals. Cell Adhesion. Disease Progression. Epithelium / metabolism. Humans. Mesoderm / metabolism. Models, Biological. Neoplasm Invasiveness. Neoplasm Metastasis. Transcription, Genetic

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19153669.001).
  • [ISSN] 1573-7233
  • [Journal-full-title] Cancer metastasis reviews
  • [ISO-abbreviation] Cancer Metastasis Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Homeodomain Proteins; 0 / Transcription Factors; 0 / ZEB1 protein, human; 0 / beta Catenin
  • [Number-of-references] 205
  •  go-up   go-down


74. Pinzani P, Mazzini C, Salvianti F, Massi D, Grifoni R, Paoletti C, Ucci F, Molinara E, Orlando C, Pazzagli M, Neri B: Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression. Melanoma Res; 2010 Aug;20(4):303-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tyrosinase mRNA levels in the blood of uveal melanoma patients: correlation with the number of circulating tumor cells and tumor progression.
  • Results were correlated with clinical data and, in a subgroup of patients, with the number of circulating tumor cells (CTC) assessed using isolation by size of epithelial tumor cells (ISET).
  • A significant correlation was found between mRNA tyrosinase levels and tumor dimension (P<0.01), disease-free and overall survival (P<0.05).
  • Tyrosinase assay by qRT-PCR is a noninvasive method for the detection of tumor progression in uveal melanoma patients.
  • [MeSH-major] Melanoma / genetics. Monophenol Monooxygenase / genetics. Neoplastic Cells, Circulating / pathology. RNA, Messenger / blood. Uveal Neoplasms / genetics
  • [MeSH-minor] Aged. Aged, 80 and over. Cell Line, Tumor. Disease Progression. Disease-Free Survival. Female. Gene Expression. Humans. Longitudinal Studies. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Uveal melanoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442676.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 1.14.18.1 / Monophenol Monooxygenase
  •  go-up   go-down


75. González-Alva P, Tanaka A, Oku Y, Miyazaki Y, Okamoto E, Fujinami M, Yoshida N, Kikuchi K, Ide F, Sakashita H, Kusama K: Enhanced expression of podoplanin in ameloblastomas. J Oral Pathol Med; 2010 Jan;39(1):103-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we examined the localization of the epithelial marker E-cadherin and the mesenchymal marker vimentin to clarify whether AMs show epithelial-mesenchymal transition (EMT).
  • RESULTS: Immunohistochemical reactivity for podoplanin was detected in the cell membrane and cytoplasm of most odontogenic tumor epithelial cells in AMs.
  • Immunoreactivity for E-cadherin was weak or negative in keratinizing cells of acanthomatous AMs, suggesting terminal differentiation of the tumor cells.
  • CONCLUSION: Expression of podoplanin in AMs is considered to be associated with neoplastic odontogenic tissues; this molecule might play a role in the collective cell migration of tumor nests in AMs.
  • [MeSH-minor] Cadherins / analysis. Cell Differentiation. Cell Membrane / ultrastructure. Cell Movement. Cytoplasm / ultrastructure. Dentigerous Cyst / pathology. Epithelial Cells / pathology. Gene Expression Regulation, Neoplastic / genetics. Humans. Intercellular Junctions / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Stromal Cells / pathology. Vimentin / analysis

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691459.001).
  • [ISSN] 1600-0714
  • [Journal-full-title] Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  • [ISO-abbreviation] J. Oral Pathol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cadherins; 0 / Membrane Glycoproteins; 0 / PDPN protein, human; 0 / Vimentin
  •  go-up   go-down


76. Melhem A, Yamada SD, Fleming GF, Delgado B, Brickley DR, Wu W, Kocherginsky M, Conzen SD: Administration of glucocorticoids to ovarian cancer patients is associated with expression of the anti-apoptotic genes SGK1 and MKP1/DUSP1 in ovarian tissues. Clin Cancer Res; 2009 May 1;15(9):3196-204
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, preclinical data implicate glucocorticoids in suppressing chemotherapy-mediated apoptosis in epithelial tumors.
  • We therefore evaluated anti-apoptotic gene expression in tumor samples from patients randomized to dexamethasone or normal saline.
  • Ovarian and omental tumor samples were collected intra-operatively before and after infusion.
  • At 30 min postinfusion, tumor samples from five patients receiving dexamethasone revealed an average SGK1 mRNA induction of 6.1-fold (SEM, +/-2.6) compared with only 1.5-fold (SEM, +/-0.4) in tumor samples from five patients receiving normal saline (P = 0.028).
  • CONCLUSION: Glucocorticoid administration to patients is associated with rapid up-regulation of SGK1 and MKP1 expression in ovarian tumors.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383827.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / R01 CA089208; United States / NCI NIH HHS / CA / P30CA014599; United States / NCI NIH HHS / CA / R01CA089208
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immediate-Early Proteins; 0 / Placebos; 0 / RNA, Messenger; 7S5I7G3JQL / Dexamethasone; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / serum-glucocorticoid regulated kinase; EC 3.1.3.48 / DUSP1 protein, human; EC 3.1.3.48 / Dual Specificity Phosphatase 1
  • [Other-IDs] NLM/ NIHMS733059; NLM/ PMC4707040
  •  go-up   go-down


77. Han G, Gilks CB, Leung S, Ewanowich CA, Irving JA, Longacre TA, Soslow RA: Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases. Am J Surg Pathol; 2008 Jul;32(7):955-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed ovarian epithelial carcinomas with clear cell and serous components are variants of high-grade serous carcinoma: an interobserver correlative and immunohistochemical study of 32 cases.
  • This could be due to significant interobserver variation in the diagnosis of CCC and other ovarian surface epithelial tumors containing clear cells.
  • Thirty-two cases previously diagnosed as CCC, high-grade ovarian serous carcinoma (SC), and mixed surface epithelial carcinoma (SEC) with clear cell and serous components were reviewed by 4 gynecologic pathologists blinded to the original diagnoses.
  • Each case was also assessed using immunohistochemical markers Wilm tumor 1, estrogen receptor, and p53.
  • Immunoreactivities of the mixed SECs were similar to those of pure SC, but significantly different from those of pure CCC for Wilm tumor 1 (P=0.0011 for both components), estrogen receptor (P=0.0003 for clear cell component, P=0.0001 for serous component), and p53 (P=0.0062 for both components).
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cystadenocarcinoma, Serous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Apoptosis. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Middle Aged. Mitosis. Neoplasm Staging. Observer Variation. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18460981.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


78. Baker SG, Kramer BS: Paradoxes in carcinogenesis: new opportunities for research directions. BMC Cancer; 2007;7:151
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • (1) the presence of large numbers of spatially distinct precancerous lesions at the onset of promotion, (2) the large number of genetic instabilities found in hyperplastic polyps not considered cancer, (3) spontaneous regression, (4) higher incidence of cancer in patients with xeroderma pigmentosa but not in patients with other comparable defects in DNA repair, (5) lower incidence of many cancers except leukemia and testicular cancer in patients with Down's syndrome, (6) cancer developing after normal tissue is transplanted to other parts of the body or next to stroma previously exposed to carcinogens, (7) the lack of tumors when epithelial cells exposed to a carcinogen were transplanted next to normal stroma, (8) the development of cancers when Millipore filters of various pore sizes were was inserted under the skin of rats, but only if the holes were sufficiently small.
  • [MeSH-major] Cell Transformation, Neoplastic / genetics. Neoplasms / etiology. Research / trends
  • [MeSH-minor] Animals. Carcinogens / pharmacology. DNA. DNA Repair. Humans. Mutation. Neoplasm Regression, Spontaneous. Rats

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14675-7 [10611270.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Feb;73(2):549-53 [1061157.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Dec;83(23):8878-82 [3466163.001]
  • [Cites] Cancer Res. 1994 Oct 15;54(20):5296-300 [7923156.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Technol Health Care. 1997 Oct;5(4):331-4 [9429273.001]
  • [Cites] Cancer Res. 1998 Oct 1;58(19):4314-23 [9766659.001]
  • [Cites] Cell. 1999 Jul 23;98(2):137-46 [10428026.001]
  • [Cites] Int J Cancer. 2005 Jan 1;113(1):168-70 [15386432.001]
  • [Cites] Br Med Bull. 1958 May;14(2):99-101 [13536368.001]
  • [Cites] Lancet. 1962 Jul 21;2(7247):107-12 [14484229.001]
  • [Cites] Prog Exp Tumor Res. 1964;5:85-133 [14317768.001]
  • [Cites] Lancet. 2005 Feb 5-11;365(9458):488-92 [15705458.001]
  • [Cites] J Biosci. 2005 Feb;30(1):103-18 [15824446.001]
  • [Cites] Breast Cancer. 2005;12(2):140-4 [15858446.001]
  • [Cites] Cancer Biol Ther. 2005 Jun;4(6):621-7 [15970666.001]
  • [Cites] Int J Cancer. 2006 Apr 1;118(7):1769-72 [16231334.001]
  • [Cites] BMC Bioinformatics. 2006;7:407 [16959042.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):225-38 [16855787.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):15121-6 [10611348.001]
  • [Cites] Lancet. 2000 Jan 15;355(9199):165-9 [10675114.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Mol Carcinog. 2000 Dec;29(4):205-11 [11170258.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1019-25 [11937181.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):197-205 [14993901.001]
  • [Cites] J Cell Sci. 2004 Mar 15;117(Pt 8):1495-502 [14996910.001]
  • [Cites] Bioessays. 2004 Oct;26(10):1097-107 [15382143.001]
  • [Cites] J Natl Cancer Inst. 1966 Aug;37(2):145-51 [5912611.001]
  • [Cites] J Natl Cancer Inst. 1972 Apr;48(4):1251-4 [5023683.001]
  • [Cites] J Natl Cancer Inst. 1973 Oct;51(4):1275-85 [4583375.001]
  • [Cites] Nature. 1981 Jan 29;289(5796):353-7 [6258076.001]
  • (PMID = 17683619.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Carcinogens; 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC1993836
  •  go-up   go-down


79. Elmslie WJ: Etiology of epithelioma among the Kashmiris.1866. Natl Med J India; 2010 Jan-Feb;23(1):49-50, 48, 54-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Etiology of epithelioma among the Kashmiris.1866.
  • [MeSH-major] Carcinoma / etiology. Skin Neoplasms / etiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20839598.001).
  • [ISSN] 0970-258X
  • [Journal-full-title] The National medical journal of India
  • [ISO-abbreviation] Natl Med J India
  • [Language] eng
  • [Publication-type] Biography; Classical Article; Historical Article; Journal Article; Portraits
  • [Publication-country] India
  • [Personal-name-as-subject] Elmslie WJ
  •  go-up   go-down


80. Lai SY, Johnson FM: Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist Updat; 2010 Jun;13(3):67-78
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although the role of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway has been most extensively studied in hematopoietic cells and hematologic malignancies, it is also activated in epithelial tumors, including those originating in the lungs and head and neck.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / metabolism. Janus Kinases / metabolism. Lung Neoplasms / metabolism. STAT Transcription Factors / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20471303.001).
  • [ISSN] 1532-2084
  • [Journal-full-title] Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • [ISO-abbreviation] Drug Resist. Updat.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interleukin-6; 0 / Intracellular Signaling Peptides and Proteins; 0 / Oligonucleotides; 0 / Receptors, Cytokine; 0 / STAT Transcription Factors; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.2 / Janus Kinases
  • [Number-of-references] 133
  •  go-up   go-down


81. Aggarwal S, Brennen WN, Kole TP, Schneider E, Topaloglu O, Yates M, Cotter RJ, Denmeade SR: Fibroblast activation protein peptide substrates identified from human collagen I derived gelatin cleavage sites. Biochemistry; 2008 Jan 22;47(3):1076-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A highly consistent trait of tumor stromal fibroblasts is the induction of the membrane-bound serine protease fibroblast activation protein-alpha (FAP), which is overexpressed on the surface of reactive stromal fibroblasts present within the stroma of the majority of human epithelial tumors.
  • In contrast, FAP is not expressed by tumor epithelial cells or by fibroblasts or other cell types in normal tissues.
  • The proteolytic activity of FAP, therefore, represents a potential pan-tumor target that can be exploited for the release of potent cytotoxins from inactive prodrugs consisting of an FAP peptide substrate coupled to a cytotoxin.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GELATIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18095711.001).
  • [ISSN] 0006-2960
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA006973; United States / NCRR NIH HHS / RR / 1S10-RR14702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / Fluorescent Dyes; 0 / Membrane Proteins; 0 / Peptide Fragments; 0 / Peptides; 0 / Recombinant Proteins; 9000-70-8 / Gelatin; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / fibroblast activation protein alpha; EC 3.4.24.- / Gelatinases
  • [Other-IDs] NLM/ NIHMS737156; NLM/ PMC4696028
  •  go-up   go-down


82. Oliva E, Alvarez T, Young RH: Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases. Am J Surg Pathol; 2005 Feb;29(2):143-56
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sertoli cell tumors of the ovary: a clinicopathologic and immunohistochemical study of 54 cases.
  • Ovarian Sertoli cell tumors are rare, and their morphologic spectrum, behavior, and factors influencing the latter are not clearly established.
  • They may be mimicked by many different tumors, some of them more frequent than Sertoli cell tumors; immunohistochemistry may aid in this differential, but its role has not been analyzed in a large series.
  • We studied the clinicopathologic features of 54 Sertoli cell tumors, including the immunohistochemical profile of 23 of them.
  • The tumors ranged from 0.8 to 30 cm, with the majority being in the range of 4 to 12 cm.
  • The predominant microscopic pattern was tubular, seen, albeit often only focally, in all tumors; other patterns were cords or trabeculae (28), diffuse (21), pseudopapillary (4), retiform (3), islands or alveolar arrangements (3), and spindled (3).
  • Delicate septa were occasionally seen and were conspicuous in areas of one tumor.
  • The stroma was abundant in 15 tumors with marked sclerosis in 4.
  • The cells usually had pale to occasionally densely eosinophilic cytoplasm, but 6 tumors were composed of cells with prominent foamy cytoplasm, falling in the category of "lipid-rich" Sertoli cell tumor, and one had cells with clear non-foamy cytoplasm.
  • Forty-four tumors were stage I (42 of them were stage Ia and 2 were stage Ic), 1 was stage II, 3 were stage III, and 6 were not adequately staged.
  • Follow-up was available for 27 patients with stage I tumors, and all were alive and well at last follow-up except for 2 patients with stage Ia and 1 with stage Ic disease.
  • Two of the three clinically malignant stage I tumors had moderate to severe cytologic atypia and brisk mitotic activity (>5 or more mitoses/10 high power fields [HPFs]), and one of these had tumor cell necrosis.
  • Among the 10 clinically benign stage I tumors with more than 5 years of follow-up, only 3 had >5 mitoses/10 HPFs, but none had more than mild cytologic atypia and none had tumor cell necrosis.
  • Two of the three stage III tumors had at least moderate cytologic atypia and brisk mitotic activity.
  • Immunohistochemical stains showed positivity for AE1/3-Cam5.2 in 15 of 23 tumors; Epithelial membrane antigen (EMA) was negative in all the tumors.
  • Inhibin was positive in 18 of 22 tumors, calretinin in 10 of 20, CD99 in 19 of 22, vimentin in 17 of 18, smooth muscle actin in 4 of 18, neuron specific enolase in 8 of 16, S-100 in 2 of 20, and chromogranin was negative in all 21 cases studied.
  • Although Sertoli cell tumors usually have a distinctive tubular pattern that facilitates the diagnosis, other patterns may occasionally predominate, causing confusion with various other primary and metastatic ovarian tumors.
  • EMA, inhibin, and chromogranin represent the most helpful triad of immunomarkers serving to exclude two common mimics of Sertoli cell tumors (endometrioid carcinoma [inhibin-; EMA+; chromogranin-] and carcinoid tumor [inhibin-; EMA+; chromogranin+]).
  • Although CD99 and calretinin are often expressed in these tumors, they are much less specific and not as helpful in the differential diagnosis.
  • Most Sertoli cell tumors are stage I, unilateral, cytologically bland, and clinically benign, but occasional examples are high stage, and about 11% of stage I tumors have worrisome histologic features that may portend an adverse outcome.
  • The tumors typically occur in young females, sometimes children who typically present with sexual precocity, and occasional patients have Peutz-Jeghers syndrome.
  • [MeSH-major] Ovarian Neoplasms / metabolism. Ovarian Neoplasms / pathology. Sertoli Cell Tumor / metabolism. Sertoli Cell Tumor / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / analysis. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644771.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


83. Chen DJ, Nirodi CS: The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res; 2007 Nov 15;13(22 Pt 1):6555-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidermal growth factor receptor (EGFR), which is frequently expressed in tumors of epithelial origin, is an important determinant of tumor responses to ionizing radiation.
  • Elevated EGFR expression and activity frequently correlate with tumor resistance to radiotherapy in patients.
  • EGFR is thought to confer tumor resistance to radiation through the activation of survival and cell proliferation pathways.
  • Targeting the DNA repair function of EGFR may serve as a therapeutic model for sensitizing tumors to radiotherapy in patients.
  • [MeSH-major] DNA Repair. DNA-Activated Protein Kinase / metabolism. Neoplasms / radiotherapy. Radiation Tolerance. Receptor, Epidermal Growth Factor / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006754.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 50519; United States / NCI NIH HHS / CA / CA 92584
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.1 / DNA-Activated Protein Kinase
  • [Number-of-references] 75
  •  go-up   go-down


84. Cirillo F: Neuroendocrine tumors and their association with rare tumors: observation of 4 cases. Eur Rev Med Pharmacol Sci; 2010 Jul;14(7):577-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroendocrine tumors and their association with rare tumors: observation of 4 cases.
  • PURPOSE: Neuroendocrine tumors are rare neoplasms, with an incidence of about 1/100,000/year.
  • The association between digestive neuroendocrine tumors and epithelial tumors is known, accounting for about 10% of cases, whilst in a very small number of other cases an association with other low incidence tumors has been observed.
  • METHODS: During the past 19 years the Rare Hormonal Tumors Group of the Istituti Ospitalieri in Cremona, Italy has observed 300 patients affected by neuroendocrine tumors.
  • We report here on four cases in which there was an unusual association with other rare neoplasms.
  • RESULTS: Overall, four of the 300 observed cases (1.3%) showed an unusual association with rare nonepithelial neoplasms:.
  • (2) Merkel cell tumor and squamous cell carcinoma of the skin;.
  • (3) medullary thyroid carcinoma, yolk sac tumor of the testis and gastrointestinal stromal tumor (GIST);.
  • (4) gastric carcinoid and gastrointestinal stromal tumor (GIST).
  • The c-kit expression, typical of GISTs but observed also in other epithelial and neuroendocrine tumors, not only broadens the possibility to gain insight into the carcinogenesis of these neoplasms, but also opens the field to possible new therapeutic opportunities using multitargeted molecules.
  • The contemporaneous presence of other lesions, such as the Merkel cell tumor and the squamous cell carcinoma of the skin can be interpreted as an answer by the cell to the same mutagenic stimulus.
  • In other cases, where a possible link is not yet found which could explain the synchronism or metachronism of low incidence neoplasms, it remains possible that the associations are entirely coincidental.
  • We await for new instruments which could help us demonstrate the possible relationships between low incidence neoplasms.
  • [MeSH-major] Neoplasms / pathology. Neuroendocrine Tumors / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20707247.001).
  • [ISSN] 1128-3602
  • [Journal-full-title] European review for medical and pharmacological sciences
  • [ISO-abbreviation] Eur Rev Med Pharmacol Sci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


85. Kruser TJ, Armstrong EA, Ghia AJ, Huang S, Wheeler DL, Radinsky R, Freeman DJ, Harari PM: Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer. Int J Radiat Oncol Biol Phys; 2008 Oct 1;72(2):534-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor xenografts in athymic nude mice were used to assess the in vivo activity of panitumumab alone and combined with radiation.
  • CONCLUSION: These studies have identified a favorable interaction in the combination of radiation and panitumumab in upper aerodigestive tract tumor models, both in vitro and in vivo.
  • These data suggest that clinical investigations examining the combination of radiation and panitumumab in the treatment of epithelial tumors warrant additional pursuit.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 2005 Feb;74(2):109-15 [15734198.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805 [15701870.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):341-54 [15864276.001]
  • [Cites] J Biol Chem. 2005 Sep 2;280(35):31182-9 [16000298.001]
  • [Cites] Radiother Oncol. 2005 Aug;76(2):157-61 [16024112.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1072-8 [16505426.001]
  • [Cites] Clin Lung Cancer. 2006 Jan;7(4):285-7 [16512986.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3162-8 [16540667.001]
  • [Cites] Cell Signal. 2006 Oct;18(10):1537-48 [16713182.001]
  • [Cites] Mol Biol Cell. 2002 Jul;13(7):2233-44 [12134064.001]
  • [Cites] Cancer Res. 2002 Aug 1;62(15):4300-6 [12154033.001]
  • [Cites] Oncogene. 2002 Oct 31;21(50):7611-8 [12400004.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1535-42 [12393476.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5057-62 [12679524.001]
  • [Cites] Int J Radiat Biol. 2003 Jul;79(7):581-5 [14530167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):984-90 [14967460.001]
  • [Cites] Radiat Res. 1993 Oct;136(1):65-70 [8210340.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):813-9 [8040028.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8 [8083133.001]
  • [Cites] Radiat Res. 1996 Jan;145(1):81-5 [8532841.001]
  • [Cites] Oncogene. 1997 Sep 4;15(10):1191-7 [9294612.001]
  • [Cites] Radiat Oncol Investig. 1997;5(4):180-6 [9327497.001]
  • [Cites] Biochim Biophys Acta. 1997 Oct 11;1358(3):289-99 [9366260.001]
  • [Cites] Clin Cancer Res. 1999 Feb;5(2):257-65 [10037173.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):781-7 [17096332.001]
  • [Cites] Clin Cancer Res. 2007 Mar 1;13(5):1552-61 [17332301.001]
  • [Cites] J Clin Oncol. 2007 May 1;25(13):1658-64 [17470858.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3712-8 [17704420.001]
  • [Cites] Nat Biotechnol. 2007 Oct;25(10):1134-43 [17921999.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1935-40 [10213503.001]
  • [Cites] Clin Cancer Res. 1999 Oct;5(10):2884-90 [10537357.001]
  • [Cites] Radiother Oncol. 1999 Aug;52(2):137-48 [10577699.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):701-8 [10690556.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4227-32 [10760290.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Dec;14(6):451-63 [10850332.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2489-95 [10851047.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2166-74 [10873065.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4343-50 [11106252.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):474-7 [11567823.001]
  • [Cites] J Biol Chem. 2001 Nov 9;276(45):42462-7 [11571274.001]
  • [Cites] Cancer Res. 1999 Mar 15;59(6):1236-43 [10096554.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3328-35 [15833866.001]
  • (PMID = 18793955.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009614-18; United States / NCI NIH HHS / CA / T32 CA009614-14; United States / NCI NIH HHS / CA / T32 CA009614-11; United States / NCI NIH HHS / CA / T32 CA009614-10; United States / NCI NIH HHS / CA / CA009614-15; United States / NCI NIH HHS / CA / T32 CA009614-15; United States / NCI NIH HHS / CA / CA009614-16A1; United States / NCI NIH HHS / CA / T32 CA009614-16A1; United States / NCI NIH HHS / CA / R01 CA113448-02; United States / NCI NIH HHS / CA / CA113448-04; United States / NCI NIH HHS / CA / R01 CA113448; United States / NCI NIH HHS / CA / CA009614-14; United States / NCI NIH HHS / CA / CA113448-01A1; United States / NCI NIH HHS / CA / R01 CA113448-03; United States / NCI NIH HHS / CA / CA009614-12; United States / NCI NIH HHS / CA / CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614; United States / NCI NIH HHS / CA / R01 CA113448-05; United States / NCI NIH HHS / CA / CA009614-11; United States / NCI NIH HHS / CA / R01 CA 113448-01; United States / NCI NIH HHS / CA / T32 CA009614-13; United States / NCI NIH HHS / CA / CA009614-18; United States / NCI NIH HHS / CA / CA009614-13; United States / NCI NIH HHS / CA / T32 CA009614-17; United States / NCI NIH HHS / CA / T32 CA009614-12; United States / NCI NIH HHS / CA / R01 CA113448-04; United States / NCI NIH HHS / CA / CA009614-10; United States / NCI NIH HHS / CA / R01 CA113448-01A1; United States / NCI NIH HHS / CA / CA113448-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Proliferating Cell Nuclear Antigen; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / panitumumab; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.11.24 / Mitogen-Activated Protein Kinases
  • [Other-IDs] NLM/ NIHMS220555; NLM/ PMC2927815
  •  go-up   go-down


86. Steller MD, Shaw TJ, Vanderhyden BC, Ethier JF: Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells. Mol Cancer Res; 2005 Jan;3(1):50-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant ovarian epithelial tumors have been shown to have decreased inhibin production relative to activin production compared with normal ovarian surface epithelial (OSE) cells and nonmalignant ovarian tumors.
  • Inhibin antagonizes the action of activin, and inhibin-deficient mice develop gonadal tumors, suggesting that inhibin may be a tumor suppressor.
  • [MeSH-major] Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Inhibins / pharmacology. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / pathology
  • [MeSH-minor] Activins / metabolism. Animals. Blotting, Western. Cell Line, Tumor. Cell Proliferation. Collagen / chemistry. Collagen / metabolism. DNA Primers / chemistry. Drug Combinations. Epithelial Cells / metabolism. Female. Humans. In Situ Nick-End Labeling. Inhibin-beta Subunits / metabolism. Laminin / chemistry. Laminin / metabolism. Mice. Mice, Nude. Neoplasm Invasiveness. Neoplasm Transplantation. Ovary / metabolism. Polysaccharides / metabolism. Proteoglycans / chemistry. Proteoglycans / metabolism. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Time Factors. Up-Regulation

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15671249.001).
  • [ISSN] 1541-7786
  • [Journal-full-title] Molecular cancer research : MCR
  • [ISO-abbreviation] Mol. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Drug Combinations; 0 / Laminin; 0 / Polysaccharides; 0 / Proteoglycans; 0 / RNA, Messenger; 0 / activin A; 104625-48-1 / Activins; 119978-18-6 / matrigel; 57285-09-3 / Inhibins; 9007-34-5 / Collagen; 93443-12-0 / Inhibin-beta Subunits
  •  go-up   go-down


87. Rumelt S, Pe'er J, Rubin PA: The clinicopathological spectrum of benign peripunctal tumours. Graefes Arch Clin Exp Ophthalmol; 2005 Feb;243(2):113-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinicopathological spectrum of benign peripunctal tumours.
  • PURPOSE: Because of the rarity of peripunctal tumours and their clinical classification as conjunctival or eyelid tumours, they have gained little attention in the literature.
  • We conducted a retrospective study to illustrate the different clinical and histopathological spectrum of peripunctal tumours seen at two oculoplastics clinics.
  • METHODS: In a retrospective interventional clinicopathologic case series study, all the charts of patients with peripunctal tumours presented at an ophthalmic oncology clinic in Jerusalem, Israel and an oculoplastics clinic in Boston, USA were reviewed.
  • The tumours were classified as epithelial and non-epithelial tumours.
  • The symptoms caused by these tumours, their pattern of growth and their management were evaluated.
  • RESULTS: Fourteen peripunctal tumours were identified.
  • Seven histopathological types of peripunctal tumours of epithelial, subepithelial or melanocytic origin causing punctal occlusion or displacement were identified.
  • The tumours included compound and junctional naevi, non-pigmented compound naevus, epithelial, subepithelial inclusion cysts, verrucous and squamous papilloma, pyogenic granuloma and oncocytoma.
  • All the tumours were benign.
  • CONCLUSIONS: Peripunctal tumours are rare.
  • The location of peripunctal tumours potentially allows their extension from the conjunctival sac into the canaliculus and vice versa.
  • Therefore, it is best to ascertain free margins when the tumour is excised.
  • [MeSH-major] Eyelid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Fr Ophtalmol. 2002 Jun;25(6):657-60 [12223957.001]
  • [Cites] Ophthalmology. 1989 Jul;96(7):994-8 [2771365.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1989;5(4):227-34 [2487228.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):479-84 [9082276.001]
  • [Cites] Am J Ophthalmol. 1993 Sep 15;116(3):385-7 [8357074.001]
  • [Cites] Sb Lek. 1966 Aug;68(8):274-8 [5975497.001]
  • [Cites] Ophthal Plast Reconstr Surg. 1994 Sep;10 (3):169-84 [7947444.001]
  • (PMID = 15558295.001).
  • [ISSN] 0721-832X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


88. Wharry CE, May MJ: Raising the price of platinum: inhibition of NFkappaB in human tumor epithelial cells. Cancer Biol Ther; 2008 Sep;7(9):1415-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Raising the price of platinum: inhibition of NFkappaB in human tumor epithelial cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. NF-kappa B / antagonists & inhibitors. Neoplasms, Glandular and Epithelial / drug therapy. Platinum / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Death / drug effects. Cell Line, Tumor. Clinical Trials as Topic. Drug Synergism. Humans. Lymphotoxin-alpha / pharmacology. Models, Biological

  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cancer Biol Ther. 2008 Sep;7(9):1407-14 [18719365.001]
  • (PMID = 18953187.001).
  • [ISSN] 1555-8576
  • [Journal-full-title] Cancer biology & therapy
  • [ISO-abbreviation] Cancer Biol. Ther.
  • [Language] eng
  • [Publication-type] Comment; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Lymphotoxin-alpha; 0 / NF-kappa B; 49DFR088MY / Platinum
  •  go-up   go-down


89. Zafirellis K, Agrogiannis G, Zachaki A: Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer. APMIS; 2008 Oct;116(10):912-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of COX-2 immunohistochemical expression evaluated by quantitative image analysis in colorectal cancer.
  • Tissue sections of primary tumors from 132 patients undergoing curative resection for colorectal cancer were immunohistochemically examined for COX-2 expression.
  • COX-2 immunoreactivity was observed in the cytoplasm of tumour epithelial cells of all colorectal cancer tissues examined.
  • No significant correlation was found between levels of intensity and extent of COX-2 staining and various clinicopathological characteristics, including age, gender, tumor location, tumor size, tumor grade, depth of invasion, lymph node status and TNM stage.
  • To analyze the prognostic value of intensity and extent of COX-2 staining, the patients were divided into four groups with respect to quartiles (< or =25; >25 to < or =50; >50 to < or =75; and >75).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma / mortality. Colorectal Neoplasms / mortality. Cyclooxygenase 2 / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132985.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


90. Krafft C, Steiner G, Beleites C, Salzer R: Disease recognition by infrared and Raman spectroscopy. J Biophotonics; 2009 Feb;2(1-2):13-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The selected topics include tumors of epithelial tissue, brain tumors, prion diseases, bone diseases, atherosclerosis, kidney stones and gallstones, skin tumors, diabetes and osteoarthritis.
  • [MeSH-minor] Algorithms. Animals. Atherosclerosis / diagnosis. Bone Diseases / diagnosis. Brain Neoplasms / diagnosis. Calculi / diagnosis. Diabetes Mellitus / diagnosis. Female. Humans. Male. Neoplasms, Glandular and Epithelial / diagnosis. Neurodegenerative Diseases / diagnosis. Osteoarthritis / diagnosis. Skin Neoplasms / diagnosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ((c) 2009 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim).
  • (PMID = 19343682.001).
  • [ISSN] 1864-0648
  • [Journal-full-title] Journal of biophotonics
  • [ISO-abbreviation] J Biophotonics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 110
  •  go-up   go-down


91. Soini Y: Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours. Histopathology; 2005 May;46(5):551-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumours.
  • To evaluate their usefulness as differentiation markers claudins 1, 2, 3, 4, 5 and 7 were studied in 116 epithelial and 92 non-epithelial tumours.
  • There were, however, tumour type-specific differences in their expression.
  • In contrast to epithelial tumours, lymphomas did not express claudins and most soft tissue tumours and naevocytic lesions were negative or showed weaker, mainly cytoplasmic positivity for some claudins.
  • Of non-epithelial tumours, claudin 5 was found only in angiosarcomas and benign vascular tumours, which also showed reactivity for claudins 2, 3 and 7, but was not expressed in any other soft tissue lesions or lymphomas.
  • CONCLUSIONS: The results show that claudins 1, 2, 3, 4, 5 and 7 can be used as markers for epithelial differentiation and to distinguish epithelial neoplasms from lymphomas and selectively also from soft tissue and naevocytic lesions.
  • Since these claudins show type-specific differential expression in epithelial tumours, they may also be of some value in distinguishing different epithelial tumours from each other.
  • [MeSH-major] Membrane Proteins / biosynthesis. Neoplasms / pathology. Receptors, Cell Surface / biosynthesis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842637.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / CLDN1 protein, human; 0 / CLDN2 protein, human; 0 / CLDN3 protein, human; 0 / CLDN4 protein, human; 0 / CLDN7 protein, human; 0 / Claudin-1; 0 / Claudin-3; 0 / Claudin-4; 0 / Claudins; 0 / Membrane Proteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


92. Weberschock T, Flux K, Gholam P, Hartschuh W, Hartmann M: [Verrucous tumor of the amputation stump]. Hautarzt; 2010 Mar;61(3):250-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Verrucous tumor of the amputation stump].
  • [Transliterated title] Verruköser Tumor am Amputationsstumpf.
  • Epithelioma cuniculatum (EC) belongs to the category of verrucous carcinomas.
  • In cases of long-standing processes with formation of exophytic, malodorous tumors with jagged edges that do not respond to conventional therapy, consideration should already be given to EC upon visual inspection.
  • The standard treatment of EC is extensive excision of the tumor with micrographic margin control.
  • [MeSH-major] Amputation Stumps / pathology. Amputation Stumps / surgery. Carcinoma, Verrucous / pathology. Carcinoma, Verrucous / surgery. Skin Neoplasms / pathology. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Derm Venereol. 1994 May;74(3):231-2 [7915474.001]
  • [Cites] J Am Acad Dermatol. 1995 Jan;32(1):1-21; quiz 22-4 [7822496.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 May;6 Suppl 1:S5-8 [18801141.001]
  • [Cites] Am J Dermatopathol. 2006 Oct;28(5):451-61 [17012926.001]
  • [Cites] J Foot Ankle Surg. 2001 Jul-Aug;40(4):225-31 [11924683.001]
  • (PMID = 20127299.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


93. Zeng J, Shi JT, Li B, Sun XL, An YZ, Li LQ, Gao F, Xu JP, Jonas JB: Epithelial tumors of the lacrimal gland in the Chinese: a clinicopathologic study of 298 patients. Graefes Arch Clin Exp Ophthalmol; 2010 Sep;248(9):1345-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epithelial tumors of the lacrimal gland in the Chinese: a clinicopathologic study of 298 patients.
  • OBJECTIVE: To examine the clinicopathologic characteristics and clinical features of epithelial tumors of lacrimal gland in China.
  • METHODS: The retrospective case series study included all 298 patients of epithelial lacrimal gland tumors which had been collected in the ophthalmic pathologic laboratory of the Tongren Hospital Beijing in the study period from 1961 to 2005.
  • RESULTS: Pleomorphic adenomas were the most common tumors (n = 213 (72%)), followed by adenoid cystic carcinoma (n = 58 (20%)), pleomorphic adenocarcinoma (n = 13 (4%)), primary adenocarcinoma (n = 8 (3%)) and other tumors (n = 6 (2%)).
  • A restriction of the eye motility was noted for 61 patients (21%), due to an involvement of the extraocular muscles with the tumor and due to a tumor-induced displacement of the globe.
  • Apart from the duration of symptoms, the tumor types did not vary significantly in age, gender, and laterality.
  • CONCLUSIONS: Based on the archives of the Beijing Tongren ophthalmo-pathological laboratory, the most common epithelial tumors of the lacrimal gland in mainland China were pleomorphic adenomas, followed by adenoid cystic carcinoma.
  • The spectrum and clinical signs of epithelial lacrimal gland tumors did not differ markedly between Chinese patients and Caucasian patients.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Pleomorphic / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1996 Oct;103(10):1606-12 [8874433.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2004 Jan;20(1):10-21 [14752304.001]
  • [Cites] Curr Opin Ophthalmol. 1995 Oct;6(5):78-85 [10159722.001]
  • [Cites] Ophthalmology. 1993 Dec;100(12):1856-60 [8259287.001]
  • [Cites] Arch Ophthalmol. 2009 Aug;127(8):1016-28 [19667339.001]
  • [Cites] Ophthalmology. 2000 Jan;107(1):164-8 [10647736.001]
  • [Cites] Zhonghua Yan Ke Za Zhi. 1997 Sep;33(5):354-6 [10451980.001]
  • [Cites] Graefes Arch Clin Exp Ophthalmol. 2003 Nov;241(11):907-13 [14579116.001]
  • [Cites] Zhonghua Yan Ke Za Zhi. 1997 Mar;33(2):92-5 [10437008.001]
  • [Cites] Ophthalmology. 1989 Apr;96(4):431-5 [2726173.001]
  • [Cites] Br J Ophthalmol. 1992 Jul;76(7):395-400 [1320923.001]
  • [Cites] Eur J Ophthalmol. 2001 Jul-Sep;11(3):301-5 [11681512.001]
  • (PMID = 20354863.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


94. Ströhlein MA, Siegel R, Jäger M, Lindhofer H, Jauch KW, Heiss MM: Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. J Exp Clin Cancer Res; 2009;28:18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of anti-tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis.
  • Peritoneal carcinomatosis (PC) from epithelial tumors is a fatal diagnosis without efficient treatment.
  • Trifunctional antibodies (trAb) are novel therapeutic approaches leading to a concerted anti-tumor activity resulting in tumor cell destruction.
  • In addition, preclinical data in mouse tumor models demonstrated the induction of long lasting tumor immunity after treatment with trAb.
  • We describe the induction of anti-tumor specific T-lymphocytes after intraperitoneal administration of trAb in patients with PC.9 patients with progressive PC from gastric (n = 6) and ovarian cancer (n = 2), and cancer of unknown primary (n = 1) received 3 escalating doses of trAb after surgery and/or ineffective chemotherapy.
  • Four weeks after the last trAb application, all patients were restimulated by subdermal injection of trAb + autologous PBMC + irradiated autologous tumor cells.
  • Immunological reactivity was tested by analyzing PBMC for specific tumor reactive CD4+/CD8+ T lymphocytes using an IFN-gamma secretion assay.In 5 of 9 patients, tumor reactive CD4+/CD8+ T-lymphocytes increased significantly, indicating specific anti-tumor immunity.
  • Follow-up showed a mean survival of 11.8 months (median 8.0 months) after trAb therapy.TrAb are able to induce anti-tumor immunity after intraperitoneal application and restimulation.
  • The induction of long-lasting anti-tumor immunity may provide an additional benefit of the intraperitoneal therapy with trAb and should be further elevated in larger clinical trials.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antibodies, Monoclonal / therapeutic use. Peritoneal Neoplasms / immunology. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Adult. Animals. Disease Progression. Dose-Response Relationship, Immunologic. Epitopes, T-Lymphocyte. Female. Humans. Injections, Intraperitoneal. Male. Mice. Middle Aged. Ovarian Neoplasms / immunology. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy. Pilot Projects. Prospective Studies. Stomach Neoplasms / immunology. Stomach Neoplasms / pathology. Stomach Neoplasms / therapy. T-Lymphocytes / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Jul;83(2):261-6 [10901380.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3899-905 [17606723.001]
  • [Cites] Eur J Surg Oncol. 2001 Mar;27(2):125-34 [11289746.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):152-6 [11461069.001]
  • [Cites] Blood. 2001 Oct 15;98(8):2526-34 [11588051.001]
  • [Cites] Semin Oncol. 2001 Dec;28(6 Suppl 18):3-11 [11774200.001]
  • [Cites] Cancer Immunol Immunother. 2002 Dec;51(11-12):621-9 [12439607.001]
  • [Cites] Br J Cancer. 2003 Dec 15;89(12):2234-43 [14676800.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):219-28 [15050953.001]
  • [Cites] J Clin Oncol. 1986 Jul;4(7):1135-47 [3522820.001]
  • [Cites] Cancer. 2000 Jan 15;88(2):358-63 [10640968.001]
  • [Cites] Oncology. 2000 Feb;58(2):96-107 [10705236.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(11):2201-9 [10829039.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1120-8 [2569032.001]
  • [Cites] J Pathol. 1990 Nov;162(3):255-60 [2266463.001]
  • [Cites] J Cell Biol. 1994 Apr;125(2):437-46 [8163559.001]
  • [Cites] Hepatogastroenterology. 1994 Apr;41(2):124-9 [8056398.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):29-42 [7826158.001]
  • [Cites] J Immunol. 1995 Jul 1;155(1):219-25 [7602098.001]
  • [Cites] Cancer Immunol Immunother. 1995 Jun;40(6):390-6 [7543021.001]
  • [Cites] Cancer Res. 1995 Oct 1;55(19):4409-15 [7545540.001]
  • [Cites] J Natl Cancer Inst. 1995 Oct 4;87(19):1463-9 [7674333.001]
  • [Cites] Cancer. 1997 Mar 1;79(5):884-91 [9041149.001]
  • [Cites] Immunol Today. 1997 Mar;18(3):127-35 [9078685.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):529-34 [10091726.001]
  • [Cites] J Immunol. 1999 Aug 1;163(3):1246-52 [10415020.001]
  • [Cites] Int J Cancer. 2005 Nov 10;117(3):435-43 [15906359.001]
  • [Cites] Br J Cancer. 2006 Jan 16;94(1):128-35 [16404366.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3085-91 [16707606.001]
  • [Cites] Gynecol Oncol. 2006 Nov;103(2):483-8 [16678891.001]
  • [Cites] Br J Surg. 2006 Dec;93(12):1530-5 [17051604.001]
  • [Cites] J Immunol Methods. 2001 Feb 1;248(1-2):149-65 [11223076.001]
  • (PMID = 19216794.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 0 / Antibodies, Monoclonal; 0 / Epitopes, T-Lymphocyte; 0 / catumaxomab; 0 / ertumaxomab
  • [Other-IDs] NLM/ PMC2644666
  •  go-up   go-down


95. Logullo AF, Lopes AB, Nonogaki S, Soares FA, Netto MM, Nishimoto IN, Brentani MM: C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer. Oncol Rep; 2007 Jul;18(1):121-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In normal breast tissue, the epithelial and fibroblast components were positive for galectin-3 mostly showing nuclear and cytoplasmic reactivity.
  • At the tumor epithelial component, galectin-3 expression was found in 46.7% of the samples with a predominant cytoplasmic staining.
  • Tumor stromal fibroblasts maintained positivity in 70 out of 92 cases (76%).
  • Epithelial galectin-3 expression cannot be considered a prognostic factor for patients with T1N0M0 breast cancer, p53 seems to be of minor relevance and c-erbB-2 expression was the best discriminator and may be a marker for aggressive clinical behavior in patients with early stage breast cancer.
  • [MeSH-major] Breast Neoplasms / metabolism. Galectin 3 / metabolism. Neoplasm Recurrence, Local / metabolism. Receptor, ErbB-2 / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Carcinoma, Ductal, Breast / metabolism. Carcinoma, Ductal, Breast / mortality. Carcinoma, Ductal, Breast / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate


96. Takahashi K, Kohno T, Matsumoto S, Nakanishi Y, Arai Y, Fujiwara T, Tanaka N, Yokota J: Clonality and heterogeneity of pulmonary blastoma from the viewpoint of genetic alterations: a case report. Lung Cancer; 2007 Jul;57(1):103-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Biphasic pulmonary blastoma is a rare lung tumor with epithelial and mesenchymal components.
  • Genetic alterations in this tumor are largely unknown, except for the presence of beta-catenin and p53 mutations and the absence of KRAS mutation.
  • To understand the molecular process of histogenesis of this tumor, a whole genome allelic imbalance (AI) scanning using a high-resolution single nucleotide polymorphism array as well as mutational analysis of the p53, EGFR, KRAS and beta-catenin genes were performed against the epithelial and mesenchymal components in the primary tumor and a metastatic tumor in a case of pulmonary blastoma.
  • AI at chromosome regions 14q24-q32 and 17p11-p13 and beta-catenin mutation were commonly detected in all tumors.
  • On the other hand, AI at chromosome regions 3p11-p14 and 9p21-p24 and p53 mutation were detected only in the mesenchymal component in the primary tumor but not in the epithelial component in the primary tumor and the brain metastasis.
  • Likewise, AI at chromosome regions 6p24-p25 and 6q14-q27 was detected in the epithelial component in the primary tumor and the brain metastasis but not in the mesenchymal component in the primary tumor.
  • Furthermore, the genetic alterations detected in the metastatic tumor were completely the same as those in the epithelial component in the primary tumor, indicating that a tumor cell(s) in the epithelial component in the primary tumor selectively metastasized to the brain.
  • These results indicate that this biphasic tumor is of monoclonal origin and the phenotypic heterogeneity of the tumor is due to the differences in the accumulated genetic alterations in each component of the tumor.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Heterogeneity. Lung Neoplasms / genetics. Pulmonary Blastoma / etiology. Pulmonary Blastoma / genetics
  • [MeSH-minor] Allelic Imbalance. Chromosomes, Human, Pair 14. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 3. Chromosomes, Human, Pair 6. Chromosomes, Human, Pair 9. Clone Cells. DNA Mutational Analysis. DNA, Neoplasm / genetics. Female. Genes, p53 / genetics. Humans. Microsatellite Repeats. Middle Aged. Neoplasm Metastasis / genetics. Neoplasm Metastasis / pathology. Polymorphism, Single Nucleotide. Sequence Analysis, DNA. beta Catenin / genetics


97. Fehm T, Becker S, Bachmann C, Beck V, Gebauer G, Banys M, Wallwiener D, Solomayer EF: Detection of disseminated tumor cells in patients with gynecological cancers. Gynecol Oncol; 2006 Dec;103(3):942-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of disseminated tumor cells in patients with gynecological cancers.
  • OBJECTIVES: The presence of disseminated tumor cells (DTC) in breast cancer patients is associated with poor prognosis.
  • However, there are limited data about the prevalence and prognostic impact of DTC in patients with gynecological tumors.
  • Presence of DTC was significantly correlated with FIGO (International Federation of Gynecology and Obstetrics) tumor stage (p<0.05).
  • CONCLUSIONS: Disseminated tumor cells seem to be a general phenomenon in epithelial tumors even though their clinical impact remains to be evaluated.
  • The hypothesis that bone marrow is the homing site of disseminated tumor cells is further supported by these data since gynecological tumors only rarely metastasize to the skeletal system.
  • [MeSH-major] Bone Marrow / pathology. Genital Neoplasms, Female / pathology. Neoplasm Recurrence, Local / pathology. Neoplastic Cells, Circulating
  • [MeSH-minor] Endometrial Neoplasms / pathology. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Neoplasm Staging. Ovarian Neoplasms / pathology. Predictive Value of Tests. Prognosis. Uterine Cervical Neoplasms / pathology

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16889820.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Kelemen LE: The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer; 2006 Jul 15;119(2):243-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FRalpha levels are high in specific malignant tumors of epithelial origin compared to normal cells, and are positively associated with tumor stage and grade, raising questions of its role in tumor etiology and progression.
  • It has been suggested that FRalpha might confer a growth advantage to the tumor by modulating folate uptake from serum or by generating regulatory signals.
  • Whether FRalpha in tumors decreases in vivo among individuals who are folate sufficient, or whether the tumor's machinery sustains FRalpha levels to meet the increased folate demands of the tumor, has not been studied.
  • Consequently, the significance of carrying a FRalpha-positive tumor in the era of folic acid fortification and widespread vitamin supplement use in countries such as Canada and the United States is unknown.
  • Epidemiologic and clinical studies using human tumor specimens are lacking and increasingly needed to understand the role of environmental and genetic influences on FOLR1 expression in tumor etiology and progression.

  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 Wiley-Liss, Inc.
  • (PMID = 16453285.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R25 CA092049; United States / NCI NIH HHS / CA / R25 CA92049
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / FOLR1 protein, human; 0 / Folate Receptor 1; 0 / Folate Receptors, GPI-Anchored; 0 / Gonadal Steroid Hormones; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0LVT1QZ0BA / Homocysteine; 935E97BOY8 / Folic Acid
  • [Number-of-references] 115
  •  go-up   go-down


99. Piga A, Gesuita R, Catalano V, Nortilli R, Cetto G, Cardillo F, Giorgi F, Riva N, Porfiri E, Montironi R, Carle F, Cellerino R: Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination. Oncology; 2005;69(2):135-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination.
  • OBJECTIVE: The aim of this study was to evaluate patient and tumor characteristics in 102 patients with unknown primary tumors (UPT) prospectively treated with a combination of carboplatin, doxorubicin, and etoposide, to identify clinical variables predictive of response and survival.
  • At multivariate analysis the number of tumor sites, bone/visceral involvement and epithelial tumor markers were significantly predictive of response; presence of pain, serum alkaline phosphatase, carboplatin AUC and response to treatment were significantly associated with survival.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasms, Unknown Primary / drug therapy. Neoplasms, Unknown Primary / pathology

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address: